Dietary Black Raspberry Supplementation as Natural Polyphenol Source Against Mild Dementia Patients with Overweight and Helicobacter pylori Infection

Dietary Black Raspberry Supplementation as Natural Polyphenol Source Against Mild Dementia Patients with Overweight and Helicobacter pylori Infection | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Article Dietary Black Raspberry Supplementation as Natural Polyphenol Source Against Mild Dementia Patients with Overweight and Helicobacter pylori Infection Chin-Kun Wang, Yohanes Tandoro, Hui-Fang Chiu, Chei-Ling Tan, and 5 more This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-3899398/v1 This work is licensed under a CC BY 4.0 License Status: Published Journal Publication published 12 Feb, 2025 Read the published version in npj Science of Food → Version 1 posted 9 You are reading this latest preprint version Abstract Alzheimer's disease (AD) is the most common form of dementia. H. pylori infection and overweight have been implicated in AD via the gut-brain axis (GBA). This study aimed to determine supplementation of BRBs has a meaningful effect on the H. pylori infection, overweight and AD development in a clinical trial setting. We conducted a randomized placebo-controlled clinical trial in patients with mild clinical dementia who also had H. pylori infection and overweight. The study was carried out over 10 weeks, consisting of an 8-week intervention period (25g powder of black raspberries, BRBs, or placebo twice a day, morning and evening) and a 2-week follow-up. The primary outcomes were changes in Clinical Dementia Rating (CDR), Urea Breath Test (UBT), and Body Mass Index (BMI). Consumption of BRBs improved cognitive functions (p0.05). Besides, BRB ingestion decreased H. pylori infection and BMI (p<0.00001 and p<0.05 respectively) while placebo group stay statistically the same (p=0.98 and p=0.25 respectively). BRBs significantly decreased inflammatory markers, improved oxidative index, adiponectin (p<0.05) compared to placebo group, while adenosine monophosphate-activated protein kinase (AMPK) and leptin did not significantly change. BRBs modulated the abundance of several fecal probiotics, particularly, Akkermansia muciniphila . Our results provided that BRBs suppressed H. pylori infection and decreased BMI and rebalancing the gut microbiome, which could improve cognitive functions in AD patients. Longer and larger randomized clinical trials of BRB interventions targeting H. pylori infection, overweight, or AD are warranted to confirm the results from this pilot trial. Trial Registration: ClinicalTrials.gov identifier: NCT05680532 Health sciences/Health care Biological sciences/Biological techniques Black Raspberry Helicobacter pylori Obesity Dementia Figures Figure 1 Figure 2 Figure 3 Introduction Alzheimer's disease (AD) is a neurodegenerative condition associated with dementia, memory and cognition impairment, and behavioral changes. AD is estimated to affect over 40 million people globally, with the prevalence of the condition anticipated to increase over the next several decades, especially in low socioeconomic status countries 1,2 . The pathophysiology of AD is not clearly understood, but genetic and environmental risk factors appear to contribute to the condition. One condition potentially related to AD development is infection with the bacterium Helicobacter pylori . AD affects nearly 4.5 billion people worldwide. This condition disproportionately affects those from disadvantaged, low socioeconomic status, or immigrant backgrounds. Lack of adequate sanitation and nutrition are among the environmental risk factors for developing infection 3–5 . H. pylori infection frequently presents as general dyspepsia. Still, it has the potential to lead to more severe conditions such as peptic ulcer disease, mucosa-associated lymphoid tissue lymphoma, and gastric adenocarcinoma, which makes it imperative to diagnose and treat H. pylori infection, given its significant global prevalence 6 . H. pylori has been implicated in AD via the gut-brain axis (GBA), a network connecting the gastrointestinal and central nervous systems via signals such as metabolites from gut microbiota, gastrointestinal hormones, and immunologic modulators 7 . As bacteria such as H. pylori infect the gastrointestinal tract, they may affect immune and metabolic signaling within the GBA and thereby lead to CNS changes. Recent studies indicate a possible link between AD and H. pylori infection, evidenced by factors such as increased anti- H. pylori IgG in AD patients 8,9 . However, the research on H. pylori in concurrence with AD remains inconclusive. Another gastrointestinal factor implicated in AD development is obesity. As with H. pylori infection, obesity may be related to AD via the gut-brain axis, especially when considering immunological factors. For instance, obesity is associated with increased susceptibility to bacterial infection, reduction in gut microbiome diversity, and subsequent pro-inflammatory profiles, a cascade that may increase the risk of developing AD 10 . Interestingly, several studies demonstrate that this risk appears to be highest when obesity is present in middle age; the reason for this remains unclear 11,12 . Together, H. pylori infection, obesity, and AD form a triad of epidemiologically overall conditions that may be linked via immunological and metabolic pathways of the GBA. However, the literature remains inconclusive regarding definitive relationships, and no previous studies have attempted to connect all three of these conditions. This merits exploration regarding treatments that can target these pathways, providing more favorable inflammatory profiles and hopefully reducing AD incidence. One potential treatment route may be a dietary modification, which has been demonstrated to affect both obesity and H. pylori infection by modulating the gut microbiome and inflammatory cascades 13,14 . Our previous research has highlighted the role of black raspberries (BRBs) in autoimmune and malignant conditions and found that in certain situations, BRBs and their metabolic components suppress pro-inflammatory markers and foster gut microbiota with less inflammatory profiles. For instance, in a murine model of ulcerative colitis, diet supplementation with BRBs was associated with reduced levels of phospho-IκBα, cyclooxygenase-2 (COX-2), toll-like receptor and prostaglandin E₂, all of which are associated with inflammation 15–19 . It is possible that the gastrointestinal effects demonstrated to result from BRBs may extend to conditions such as obesity and H. pylori , both of which are also strongly associated with inflammation. The purpose of this study was to determine whether supplementation of diet with BRBs has a meaningful effect on the gastrointestinal conditions of H. pylori infection and overweight and the development of AD in a clinical trial setting. Methods Clinical trial The clinical trial protocol was approved by the IRB at Chung Shan Medical University, Taiwan (protocol number CS2-21103, Title: The improvement of black raspberry in obese and mild AZ patients infected with H. pylori ). Inclusion criteria for this study were as follows: BMI ≥ 27; waist circumference for men ≥ 90 cm, women ≥ 80 cm; body fat for men ≥ 25%, women 30%; a 13 C urea breath test (UBT) test value > 10% indicating H. pylori positivity; and clinical dementia rating (CDR) = 0.5. Exclusion criteria were as follows: BMI < 27; severe chronic disease (liver disease, cardiovascular disease, kidney disease); taking medications known to affect lipid metabolism or possess anti-inflammatory effects; gastrointestinal disorder; surgery; alcohol abuse; smoking; pregnant or lactating; taking berry-related supplementation or having known allergies or hypersensitivity to berries, including BRBs; taking antibiotics/ corticosteroids in the last 4 weeks; taking NSAIDs or COX-2 inhibitors due to external clinical conditions; and/or prior history of H. pylori infection treated with triple therapy. In total, 21 subjects were recruited for the study; 11 (8 males and 3 females) in the berry group and 10 (4 males and 6 females) in the placebo group. Subjects were aged 60–85 years old. Those in the BRB group received 25 g of black raspberry powder dissolved in 240 mL of water twice a day, once after breakfast and once after dinner, resulting in total consumption of 50 g of black raspberry powder per day. Subjects in the placebo group received 25 g of dextrin twice per day, administered in the same way as the black raspberry powder to a total of 50 g of dextrin per day. Each 50 g of black raspberry powder was estimated to contain (mean ± SD) 1926.50 ± 547.00 mg/g of phenols, 336.50 ± 11.00 mg/g of flavonoids, 1101.50 ± 51.00 mg/g of anthocyanins, 5581.00 ± 715.00 mg/g of condensed tannins, and 10.49 g of fiber ( Supplementary Table 1 ). The study was conducted over 10 weeks, consisting of an 8-week intervention period and a 2-week follow-up. At week 0, anthropometric measurements were taken of weight, height, BMI, waist circumference, hip circumference, blood pressure, body fat, and triceps skinfold thickness. Patients were asked to maintain their regular diets while on trial, and they kept a 3-day dietary record consisting of 2 weekdays and 1 weekend day. Blood sampling was also taken to assess lipid profile, cytokine levels, inflammatory markers, antioxidant index, thyroid function, liver function, kidney function, and blood chemistry. A 13 C UBT, fecal sampling, and CDR were also performed at week 0. At week 2, anthropometric measurements and dietary recall were repeated. At week 4, anthropometric measurements, dietary recall, and blood sampling were performed. At week 6, anthropometric measurements and dietary recall were performed. At week 8, anthropometric measurements, dietary recall, blood and fecal sampling, and 13 C UBT and CDR were performed. At the week 10 follow-up, anthropometric measurements, dietary recall, and blood sampling were performed. Fecal Sample Analysis Fecal samples from the subjects consumed BRBs were collected at baseline and end of the intervention. The fecal sample is prepared in the Colon Heal bacterial detection kit (Aging and Disease Prevention Research Center, Fooyin University, Kaohsiung, Taiwan) following manufacturer's instruction. 16S library pool was performed using Illumina MiSeq system library preparation instruction. Forward (F)/reverse (R) primers (F: 5'-TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGCCTACGGGNGGCWGCAG-3’/R: 5'-GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGGACTACHVGGGTATCTAATCC-3') with overhang sequence were used for metagenome analysis to generate Illumina 16S library by two-step polymerase chain reaction. 16S libraries generated were pooled and sequenced using MiSeq with MiSeq V3 reagent kits and analyzed with MiSeq Reporter Software (MSR). Classification of the result is based on the Greengenes database ( http://greengenes.lbl.gov/ ). The mean of relative abundance was compared at the phylum, genus, and species levels. Preparations of different BRB extracts Procedures to prepare BRB crude extract, crude extract treated with gelatin, and tannins fraction are shown in Supplemental Fig. 1 . Phenolic contents in different BRB extracts are listed in Supplemental Table 1 . AGS cell model Human gastric adenocarcinoma cell culture (AGS cell) was purchased from American Type Culture Collection (ATCC) and cultured in F12 (Ham’s media Kaighn Modification, Cytiva) medium containing 10% of Fetal Bovine Serum 37 o C humidified incubator with 5% CO2. Cell viability The cell viability was evaluated using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) method. AGS cells (2 × 10 5 /mL) were seeded into a 96-well plate and incubated overnight. Increasing concentrations of BRB crude and gelatin treated crude extracts (0, 50, 100, 250, 500, 1000 µg/mL in serum-free medium with 0.05 Dimethyl Sulfoxide (DMSO)) or H. pylori (OD 600 0.3 (1 x 10 8 CFU/ mL)) were co-cultured with AGS cells and incubated at 37°C for 24 hours. After 24 hours, the medium was removed and changed with 100 µL (0.5 mg/mL) of MTT in phosphate-buffered saline (1X PBS) and cultured at 37°C for 3 hours. Finally, the cells were mixed with 100 µL DMSO and shaken for 10 min (to dissolve formazan crystals), and the absorbance was measured using a microplate reader at 570 nm. The blank wells were prepared with no cells and positive control wells were 50 µg/mL Amoxicillin. The cell viability (%) was calculated with the following equation: Cell viability (%) = Absorbance (Sample – Blank)/ Absorbance (Control – Blank) x 100% H. pylori Adhesion AGS cells were seeded in 24-well plates and incubated overnight. Increasing concentrations of BRB crude and gelatin treated crude extract (0, 50, 100, 250, 500, 1000 µg/mL) or amoxicillin (0.05 mg/mL) and H. pylori suspension were added to each well and incubated for 6 hours in a humidified CO2 incubator. The nonadherent bacteria were washed off with 1X PBS solution. The final suspension was collected after 6 hours of incubation to quantify the bacterial viability in the urease reagent and read at 560 and 600 nm. Adherent bacteria were evaluated with urease reagent (3 mM PBS pH 5.8; 2% urea and 4 µg/mL phenol red, pH 5.0) and read absorbance at 560 nm and calculated by the formula: Anti-adhesive activity (%) = (control absorbance − sample absorbance) ∕ control absorbance × 100% CagA, VacA western blot Analysis of CagA and VacA expression detected using western blot analysis. AGS cells were seeded in 10 cm dish plates and incubated overnight. Increasing concentrations of BRB crude and gelatin treated crude extract (0, 0.05, 0.1, 0.25, 0.5, and 1 mg/mL) or amoxicillin (0.05 mg/mL) and H. pylori suspension were added to each plate and incubated for 6 hours. All cells were collected and lysed using ice-cold lysis buffer, and cell protein was collected after centrifugation (3000 RPM, 10 minutes, 4 o C). Cell proteins were separated in 8% polyacrylamide gel and blotted to polyvinylidene difluoride membrane (PVDF). The membrane was blocked in 5% skim milk in TBS buffer containing 0.2% Tween-20. The membrane was incubated with anti-beta actin monoclonal antibody (SC-47778, Santa Cruz Biotechnology, USA), anti-CagA monoclonal antibody (SC-28368, Santa Cruz Biotechnology, USA) and anti-VacA monoclonal antibody (SC-32746, Santa Cruz Biotechnology, USA) overnight at 4 o C. After the removal of the primary antibody, the membrane was soaked in HRP-conjugated anti-mouse secondary antibody (Invitrogen, Thermo Fischer, USA) for 1 hour at room temperature. Reacted band of the targeted protein was revealed using enhanced chemiluminescence (ECL) using ECL commercial kit (G-Biosciences, USA). IL-8 secretion IL-8 content was determined using a commercialized IL-8 ELISA kit (Biolegend, California, USA) by following the manufacture's protocol. Each sample was tested in triplicate 3T3-L1 pre-adipocyte and mature 3T3-L1 adipocytes 3T3-L1 was purchased from American Type Culture Collection (ATCC) and cultured in DMEM (Gibco) medium containing 10% bovine calf serum and differentiated into mature adipocytes by DMEM containing 0.5 mM IBMX (3-isobutyl-1-methylxanthine), 1 mM DEXA and 10 mg/mL insulin at 37 o C humidified incubator with 5% CO2. Cell viability of 3T3-L1 pre-adipocytes The cell viability was evaluated using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) method. 3T3-L1 pre-adipocytes were seeded into a 96-well plate and incubated overnight. Increasing BRB crude extract concentration, gelatin treated crude extract, and tannin fraction (0, 0.1, 0.5, 1, 2, 5, 10, 15, and 20 mg/mL) were added and incubated at 37°C for 24 hours. After 24 hours, the medium was removed and changed with 100 µL (0.5 mg/mL) of MTT in phosphate-buffered saline (1X PBS) and cultured at 37°C for 4 hours. Finally, the cells were mixed with 100 µL DMSO and shaken for 10 min (to dissolve formazan crystals), and the absorbance was measured using a microplate reader at 570 nm. The blank wells were no cells. The cell viability (%) was calculated with the following equation: Cell viability (%) = Absorbance (Sample – Blank)/ Absorbance (Control – Blank) x 100% Oil-red staining in mature 3T3-L1 adipocytes for lipid accumulation Mature adipocytes in 24 wells were washed twice with PBS and fixed using 10% formaldehyde solution for 1 hour. After 1 hour, cells were washed twice using PBS, and 0.5% oil red solution (in isopropanol) were added and incubated for 15 minutes to stain the lipid droplets. Cells were washed with dd H 2 O to remove unbound oil red. Isopropanol was added to dissolve the oil red and shake for 10 minutes. 100 µL of the solution was transferred to 96 wells, and read absorbance at 490 nm and lipid accumulation were calculated with the following equation: Lipid accumulation (%) = Absorbance (Sample)/ Absorbance (Control) x 100% Statistical analysis The sample size was calculated to assess difference among groups (α: 0.05) with 5% reduction of UBT value using 95% confidence interval and 80% power (1-β) and according to calculation each group need at least 6 subjects and considering dropout rate of 20%, 10 subjects in each group is used. Repeated measure ANOVA and chi-squared test is used to assess difference within the group (intervention vs baseline) as appropriate. Results obtained from cells were analyzed with one-way ANOVA of SPSS (version 26, SPSS Inc). Significance difference is identified with p < 0.05 Results BRB consumption improves cognitive function in patients with mild dementia due to Alzheimer's disease associated with decreased inflammation and oxidative stress. We conducted a placebo-controlled clinical trial in patients with mild clinical dementia due to AD who also had H. pylori infection and were overweight (aged 60–85 years old.). The baseline patient demographics show that age, Clinical Dementia Rating (CDR), body mass index (BMI), and urea breath test (UBT) are statistically the same (Table 1 ). Patients were randomized to either BRB or placebo group. BRB group consumed 8-week BRBs (25g, twice a day, morning and evening, n = 11, 8 males and 3 females). The placebo group consumed a placebo powder (25g, twice a day, morning and evening, n = 10, 4 males and 6 females). After the 8-week intervention, all patients were followed up for 2 weeks. Table 1 Baseline patient demographics Placebo BRBs p value Age 78.9 ± 3.0 77.5 ± 3.0 0.32 Gender Male 4 8 0.20 Female 6 3 BMI 28.5 ± 0.9 29.5 ± 1.9 0.14 UBT 23.0 ± 1.8 22.1 ± 4.2 0.50 CDR 0.5 ± 0.0 0.5 ± 0.0 1.00 The results are expressed as mean ± SD. BMI: body mass index; UBT: urea breath test; CDR: clinical dementia rating Clinical Dementia Rating (CDR) values did not change in the placebo group, but those in the BRB group had an average CDR of 0 at the end of the 8-week intervention (Fig. 1 A). It should be noted that neither amyloid beta nor p-tau was detectable in plasma from this patient population using an ELISA-based assay (data not shown). We then determined the effects of BRBs on Aβ-induced neurotoxicity in cultured neurons. Aβ42 oligomer treatment led to neurotoxicity in HT22 neuron cells, and BRB ethanol extract protected against Aβ-induced damage (Fig. 1 B). It is possible that ethanol extract of BRBs contains anthocyanins that have been shown to cross the blood-brain barrier to protect the brain from Aβ toxicity ( 35 ). BRBs decreased Proteobacteria and Firmicutes to Bacteroidetes ratio in the feces (Fig. 2 A). Further, BRBs decreased fecal Helicobacter bacteria abundance (Fig. 2 B), but increased fecal probiotics such as Lactobacillus reuteri , Bifidobacterium longum (Fig. 2 C). Most interestingly, Akkermansia muciniphila abundance increased in all subjects who consumed BRBs (Fig. 2 D). 13 C UBT was significantly lower at week 8 in the BRB group when compared to baseline (Table 2 ). However, this difference was resolved in week 10. Inflammatory markers, reflected by tumor necrosis factor α (TNF-α), interleukin-1β (IL-1β), interleukin-8 (IL-8), cyclooxygenase-2 (COX-2), and inducible nitric oxide synthase (iNOS) were measured at weeks 0, 4, and 8. At week 4, levels of TNF-α, IL-8, COX-2, and iNOS were significantly lower than at baseline, whereas levels of IL-1β were significantly higher. At week 8, levels of TNF-α, IL-8, and COX-2 were significantly lower than baseline, with IL-1β continuing to be significantly higher than levels at both baseline and week 4. The oxidative index was quantified by superoxide dismutase (SOD), catalase (CAT), thiobarbituric acid reactive substances (TBARS), and Trolox Equivalent Antioxidant Capacity (TEAC). At weeks 8 and 10, SOD, CAT, and TEAC levels were significantly higher than at baseline, but TBARS levels were significantly lower than at baseline. Table 2 BRB consumption decreased UBT and inflammatory markers, and oxidative indexes Week 0 Week 8 Follow up UBT BRBs 22.12 ± 4.14 9.36 ± 6.36* 16.82 ± 10.46* Placebo 22.98 ± 1.78 22.99 ± 2.065 22.88 ± 3.07 Inflammatory markers TNF-α (pg/mL) BRBs 19.76 ± 4.65 6.85 ± 3.27* 7.97 ± 2.17* Placebo 19.81 ± 2.21 19.59 ± 2.31 19.41 ± 2.39 IL-1β (pg/mL) BRBs 0.16 ± 0.07 0.12 ± 0.05* 0.18 ± 0.05* Placebo 0.19 ± 0.08 0.19 ± 0.05 0.18 ± 0.05 IL-8 (pg/mL) BRBs 7.61 ± 5.10 4.63 ± 3.63* 5.94 ± 3.09 Placebo 7.67 ± 4.25 7.86 ± 4.90 7.79 ± 4.23 COX-2 (ng/mL) BRBs 1.74 ± 0.71 0.87 ± 0.56* 0.88 ± 0.50* Placebo 1.68 ± 0.65 1.64 ± 0.72 1.69 ± 0.62 iNOS (ng/mL) BRBs 21.15 ± 8.50 20.27 ± 10.28 22.37 ± 11.95 Placebo 21.73 ± 7.44 22.00 ± 7.75 21.21 ± 7.24 Oxidative indexes SOD (U/mL) BRBs 696.42 ± 35.30 784.86 ± 46.13* 743.84 ± 55.59* Placebo 690.72 ± 34.84 695.44 ± 39.65 691.54 ± 41.35 CAT (U/mL) BRBs 346.11 ± 14.60 360.84 ± 8.26* 360.21 ± 9.22* Placebo 352.58 ± 14.16 351.95 ± 11.30 351.14 ± 9.03 TBARS (µmol/L) BRBs 4.14 ± 1.20 1.20 ± 0.35* 1.97 ± 0.62* Placebo 4.20 ± 0.57 4.25 ± 0.74 4.30 ± 0.90 TEAC (µmol Trolox/L) BRBs 1319.77 ± 191.90 1840.68 ± 188.73* 1740.09 ± 155.99* Placebo 1250.90 ± 185.14 1232.00 ± 199.59 1238.40 ± 237.70 The results are expressed as mean ± SD. *Difference between different times and week 0 within the same group, P < 0.05. Regarding changes in BMI, at week 4, the BRB group had a significantly lower body weight and BMI (p < 0.05) compared to their week 0 measurements (Table 3 ). Adenosine monophosphate-activated protein kinase (AMPK) and leptin did not significantly change from baseline across the course of the study, but adiponectin was significantly increased from baseline at both weeks 8 and follow-up (p < 0.01) (Table 3 ). Table 3 Body weight, BMI, body fat, AMPK, adiponectin, and leptin levels Week 0 Week 4 Week 8 Follow up Body weight (kg) BRBs 83.41 ± 10.39 82.65 ± 9.82* 82.90 ± 10.37 83.15 ± 10.09 Placebo 74.14 ± 8.47 73.90 ± 7.72 73.45 ± 7.49 73.83 ± 7.96 Body Fat (%) BRBs 30.61 ± 5.88 30.33 ± 6.17 30.14 ± 6.16 30.17 ± 5.76 Placebo 32.34 ± 5.70 31.92 ± 6.53 32.59 ± 5.72 32.70 ± 5.87 BMI (kg/m 2 ) BRBs 29.47 ± 1.92 29.21 ± 1.97* 29.30 ± 2.06 29.41 ± 2.01 Placebo 28.46 ± 0.92 28.38 ± 0.99 28.23 ± 1.12 28.35 ± 1.06 AMPK (pg/dL) BRBs 9142.50 ± 6734.93 9408.57 ± 5844.41 9694.09 ± 7408.22 9641.23 ± 6664.65 Adiponectin (µg/mL) BRBs 459.33 ± 318.14 651.27 ± 546.30 2394.65 ± 1418.26* 2134.89 ± 1153.37* Leptin (µg/mL) BRBs 5055.98 ± 2969.55 4845.42 ± 2049.15 4704.60 ± 2689.98 4866.47 ± 3584.98 The results are expressed as mean ± SD. *Difference between different times and week 0 within the same group, P < 0.05. AMPK: adenosine monophosphate-activated protein kinase Further, neither the BRB nor placebo groups had significant changes in blood lipid profile from their respective baselines at these time points ( Supplemental Table 2 ). Insulin, Homeostatic Model Assessment for Insulin Resistance score (HOMA-IR, quantified as [FBG * insulin]/405), and hemoglobin A1c (HbA1C) did not significantly change from baseline in the BRB and placebo groups ( Supplemental Table 3 ). However, FBG was significantly higher compared to baseline at week 4 and week 8 in the BRB group (p < 0.05, p < 0.01, respectively). Blood chemistry of subjects, reflected by glutamate oxaloacetate transaminase (GOT), glutamate pyruvate transaminase (GPT), blood urea nitrogen (BUN), creatinine, uric acid (UA), and creatinine phosphokinase (CPK), were not significantly different in either group across time points ( Supplemental Table 3 ). Mineral content was reflected by sodium (Na), potassium (K), chloride (Cl), and calcium (Ca) levels. K levels were significantly higher at week 4 compared to baseline in the BRB group (p < 0.01) ( Supplemental Table 4 ). Na was significantly lower at follow-up compared to baseline in the BRB group (p < 0.05). At week 4, those in the BRB group had a significantly lower rump circumference (RC) and triceps skin fold (TSF) (p < 0.05) compared to their week 0 measurements ( Supplemental Table 5 ). At week 8, those in the BRB group had a significantly lower body fat percentage, RC, and mid-arm circumference (MAMC) compared to their week 0 measurements (p < 0.05). Aside from these differences, waist circumference (WC), RC, MAMC, and TSF were not significantly different within the two groups at various recording times. At week 4, DBP was significantly lower than the baseline in the BRB group (p < 0.05). While this difference resolved, SBP became significantly lower from baseline in the BRB group at follow-up (p < 0.05) ( Supplemental Table 6 ). BRB extracts rescued H. Pylori -induced damages in cultured AGS cells An MTT assay was performed on applying crude BRB extract to AGS cells and H. pylori to assess for protective effects of BRBs against H. pylori , with cell viability assessed at 24 hours (Fig. 3 A). When H. pylori were added with no BRB extract or amoxicillin, cell viability decreased at 24 hours. However, when increasing concentrations of crude BRB extract were added to H. pylori and the AGS cells, cells were rescued. A similar effect was seen with the gelatin-treated crude extract. H. pylori adhesion was measured with varying doses of crude and gelatin-treated crude extracts. Increasing doses of crude and gelatin-treated crude extract reduced H. pylori adhesion (Fig. 3 B). Analysis was performed on proteins associated specifically with H. pylori . Western blot was performed to assess the expression of cytotoxin-associated protein A (CagA), associated with the induction of intestinal metaplasia and gastric adenocarcinoma 20 . CagA expression was significantly reduced by both crude and gelatin-treated crude extract (Fig. 3 C). Western blotting was also utilized to determine the expression of vacuolating cytotoxin A (VacA), another H. pylori product that modulates the function of immunologic cells and is associated with H. pylori colonization, peptic ulcer disease, and gastric adenocarcinoma 21 . VacA expression was significantly decreased by crude extract and crude extract treated with gelatin (Fig. 3 C). Lastly, interleukin-8 (IL-8) expression has been shown to be induced by H. pylori infection; the upregulation of IL-8 related to H. pylori is associated with gastritis and possibly gastric malignancies 22,23 . When H. pylori was added to the AGS cell culture, IL-8 expression was significantly increased (Fig. 3 D). Both extracts significantly decreased H. pylori -induced IL-8. Overall, both crude extract and crude extract-treated with gelatin decreased H. pylori -induced damages, including increasing cell viability, decreasing H. pylori adhesion and expression of CagA, VacA, and IL-8 in cultured AGS cells (Fig. 3 A- 3 D). BRB extracts promoted 3T3-L1 pre-adipocyte viability and decreased lipid accumulation in 3T3-L1c mature adipocytes 3T3-L1 pre-adipocytes were incubated with crude extract, gelatin-treated crude extract, and tannin fraction. A significant increase in viability was seen in 3T3-L1 pre-adipocytes treated with all three extracts (Fig. 3 E). Oil-red staining was then performed to assess the effects of those three extracts on lipid accumulation in 3T3-L1 mature adipocyte cells. All three BRB extracts significantly decreased lipid accumulation (Fig. 3 F). Discussions The purpose of this study was to assess whether BRBs had meaningful effects on markers of H. pylori infection and obesity, thereby impacting AD dementia. We conducted a randomized, placebo-controlled clinical trial, which examined the effects of BRBs on obese subjects who were H. pylori positive and had AD as measured by a CDR of 0.5. BRBs significantly improved cognitive function by moving CDR from 0.5 to zero and decreased UBT and BMI. These effects are associated with significant anti-inflammatory and antioxidant capacity. Although neither amyloid beta nor p-tau was detectable in plasma from this AD patient population using an ELISA-based assay (data not shown), our results could suggest that they could be at an early stage of AD. More sensitive ultrasensitive platforms, including SIMOA, IMR, MSD, and Elecsys immunoassays, that overcomes the complex interferences of blood proteins, heterophilic antibodies, and low target biomarkers 24 , will be used to confirm the levels of blood amyloid beta and p-tau in this AD population in the future. Gut microbiota is a complex microorganism in the human GI tract that plays a crucial role in maintaining health 25 . Gut microbiota can help to metabolize some indigestible dietary components and to prevent pathogen colonization in the GI tract 26 . Gut microbiota mainly comprises two major phyla, Firmicutes and Bacteroidetes , and some minor phyla, such as Proteobacteria , and Actinobacteria 27 . Alteration of gut microbiota can influence different metabolic disorders, the immune system, and also the central nervous system through the gut-brain axis 28 . Recent studies show that there are links between gut microbiota and Alzheimer’s disease. Gut microbiota is affected by lifestyle, including food intake and habits. Host dietary components are used as substrates and energy sources to prevent pathogenic bacteria and produce beneficial metabolites 29 . Proteobacteria is one of the gut microbiota phyla that comprises several human pathogens 30 . Pathogenic infections such as Chlamydophila pneumoniae, Helicobacter pylori, Toxoplasma gondii , and others might contribute to the pathogenesis of Alzheimer’s disease 31 . Besides Proteobacteria , gut dysbiosis is linked to AD progression. Gut dysbiosis is a phenomenon where gut microbiota is altered that mainly showed by increasing ratio of Firmicutes to Bacteroidetes 32,33 . Gut dysbiosis is associated with several AD pathology, such as accumulation of intestinal amyloid precursor protein (APP), induction of systemic inflammation by proinflammatory neurotoxin and bacterial lipopolysaccharide (LPS), and alteration of blood-brain barrier (BBB) 33,34,35,36 . BRBs contain high amounts of polyphenols which can act as antimicrobial agent, especially for H. pylori 37,38 . Helicobacter , particularly Helicobacter pylori is a gram-negative bacterium that mainly resides in the gastric and induces several inflammatory responses due to its virulence factor 39 . H. pylori infection can cause disruption of tight junction, and this disruption can lead to increased proinflammatory cytokines and harmful metabolites (e.g. bacterial amyloids and trimethylamine-N-oxide (TMAO)) 40 . These harmful substances produced by pathogens enter the circulatory system, disrupt BBB and induce an immune response in the central nervous system 33 . H. pylori can induce a neuroinflammatory response in the C57BL6 WT mice through circulating proinflammatory cytokines 41 . Eradication of H. pylori from AD subjects result in improved cognition compared with AD patients who did not receive H. pylori eradication therapy 42 . On the other hand, BRB intervention also increased probiotics such as Lactobacillus and Bifidobacterium. Probiotics play an essential role in maintaining gut health due to their ability to metabolize undigested food components and produce metabolites such as gamma-aminobutyric acid (GABA) and short-chain fatty acids (SCFA) 43 . GABA is an inhibitory neurotransmitter that reduces stress and anxiety 44 . In Alzheimer’s patients, GABA concentration is significantly decreased and causes cognitive impairment 45 . SCFA are the metabolites from dietary fiber fermentation derived from gut microbiota and linked to gut-brain interaction 46 . SCFA can cross the BBB and repair neuronal by upregulating cyclic-AMP response element binding protein (CREB) and brain-derived neurotrophic factor (BDNF), inhibiting inflammatory response in the central nervous system, reducing Aβ aggregation into neurotoxic oligomer, reducing tau protein hyperphosphorylation and reducing the cognitive impairment in AD subjects 46,47 . Our study result show that BRB supplementation increase Bacteriodetes and probiotic concentration. This result might indirectly link to increase production of GABA and SCFA due to Bacteriodetes such as Bacteriodes and Parabacteroides, and Bifidobacterium ability to produce GABA 48, 49 and lactic acid bacteria ( Lactobacillus and Bifidobacterium ) to produces SCFA 50 but further study is needed to support this statement. Akkermansia muciniphilla is a gram-negative bacterium belonging to Verrucomicrobiota , constitutting 1–4% of the total fecal microbiome 51,52 . Akkermansia muciniphilla can degrade intestinal mucin and produce acetate and propionate as substrates for other gut microbiome and the host 53 . Akkermansia muciniphilla abundance is decreased in obesity, inflammation, and diabetes in the human GI tract 54 . BRBs are rich in polyphenols, and several studies have shown that polyphenols promote the growth of Akkermansia muciniphilla in the mice GI tract 55–57 . Interestingly, we showed that BRBs increased the abundance of Akkermansia muciniphila , a bacterium associated with reduced inflammation, and decreased in patients with mild cognitive decline 58 , that could delay the cognitive decline and improved CDR in patients with Alzheimer's disease. UBT values and inflammatory markers provided indices of efficacy against H. pylori infection. Overall, UBT values were meaningfully improved by BRB intervention, but this effect did not persist when BRB supplementation was discontinued. While most of the inflammatory markers, excluding iNOS, did indicate less inflammatory profiles with continued BRB supplementation, the post-intervention impacts were not explored, so additional study is needed to assess whether the alterations in inflammatory profile continue to benefit even after BRB treatment. These results indicate that BRBs may exert some degree of defense against H. pylori infection, but the results only support these benefits so long as BRBs continue to be consumed in the diet. Assays were performed first on AGS and 3T3-L1 pre-adipocyte cell models to explore whether BRBs might have tangible results in human patients. While BRBs significantly improved the viability rates of AGS cells exposed to H. pylori . Further, both crude and gelatin-treated crude extracts reduced the adhesion rates of H. pylori in the AGS cell cultures. However, here it is important to note that the amoxicillin control also showed the same level of a significant reduction in adhesion rates as BRBs, suggesting that BRBs were similarly, but not more or less effective, than amoxicillin alone in reducing adhesion rates of H. pylori . Both crude extract and crude extract treated with gelatin decreased CagA and VacA protein expressions. These results suggest that while BRB extract can provide statistically comparable effects when compared to amoxicillin in reducing the expression of these H. pylori genes, it must be administered at sufficiently high doses. However, considering that amoxicillin is currently part of status quo treatment for H. pylori based on extensive research demonstrating its effectiveness, further research is needed to determine whether BRBs are a reasonable alternative to amoxicillin, seeing as they do appear to provide a significant additional benefit against H. pylori infection in AGS cells. Another route of exploration may involve seeing if the effects of amoxicillin and BRBs are cumulative; that is, whether the supplementation with BRBs of a pre-established amoxicillin regimen to treat H. pylori might be more effective than amoxicillin alone. The 3T3-L1 pre-adipocyte and mature adipocyte models, crude extract, gelatin-treated crude extract, and tannins fraction were all effective. This result supports the notion that crude BRB extract is sufficient to show the effects. Tannins in the extract are essential. Gelatin-treated crude extract or tannins fraction and that more components than just tannins are likely active in reducing lipid accumulation. It is expected that the effects of crude BRB extract cannot be attributed to tannins alone. Still, more research will be needed to determine which additional components confer the other advantage to crude BRB extract. Given the activity of BRBs against H. pylori , as demonstrated by the AGS cells, and against obesity, as shown by the 3T3-L1 pre-adipocyte cells, it was anticipated that they might exert similar effects on actual patients. Although BRBs did affect physiologic markers of obesity, including body weight, BMI, body fat, RC, MAMC, and TSF, these effects did not persist into the follow-up stage. Interestingly, while body fat, RC, and MAMC did a downtrend throughout the intervention, reaching significance by week 8, the other markers did not show trends with continued intervention. This finding suggests that adding BRBs to the diet provided variable benefits, with some lasting only temporarily despite additional BRB consumption and others taking some time to manifest. Overall, all benefits were lost within 2 weeks after the intervention was concluded, so continued consumption of BRBs appears to be necessary. BRBs did not confer any significant disadvantage as assessed by the obesity markers. Interestingly, SBP only showed a significant reduction at follow-up, 2 weeks post-intervention, while DBP was only reduced at week 4. BRBs did not exert meaningful effects on blood lipid profiles. They did not affect markers of diabetes other than fasting blood glucose, which was significantly increased with an upward trend throughout the intervention. This trend merits further exploration as increased FBG is not a desirable result; while the average levels within subjects were maintained below pre-diabetes levels, it is uncertain whether continued consumption of BRBs would have breached that threshold. One of the most significant changes related to obesity was seen in adiponectin levels, which substantially increased after both 8 weeks of treatment and 2 weeks post-intervention. Low adiponectin levels are associated with obesity, diabetes, hyperlipidemia, and other conditions that place patients at high risk for cardiovascular disease, while high adiponectin levels are associated with a healthier metabolic profile, so it appears that BRBs resulted in a meaningful benefit here 59,60 . In conclusion, our results provide the first evidence that BRBs enhanced fecal Akkermansia muciniphila abundance and protectively altered parameters of H. pylori infection and obesity, leading to dampened inflammation and oxidation, which could result in improved cognitive functions in AD patients. Longer and larger randomized clinical trials of BRB interventions targeting H. pylori infection, obesity, or AD are warranted to confirm the results from this pilot trial. Declarations Consent Statement: The authors confirmed that all human subjectslprovided informed consent. Acknowledgments This work was supported by NIH grants CA148818 and USDA/NIFA 2020-67017-30843 (to L.-S. Wang) , and also supported by National Science and Technology Council of Taiwan grants 111-2320-B-040-003-MY3 (to C.-K Wang). Conflicts of Interest All authors declare the absence of any competing interests. References Global, regional, and national burden of Alzheimer's disease and other dementias, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. Jan 2019;18(1):88–106. doi: 10.1016/s1474-4422(18)30403-4 Scheltens P, De Strooper B, Kivipelto M, et al. Alzheimer's disease. Lancet . Apr 24 2021;397(10284):1577–1590. doi: 10.1016/s0140-6736(20)32205-4 Brown LM. Helicobacter pylori: epidemiology and routes of transmission. Epidemiol Rev. 2000;22(2):283–97. doi: 10.1093/oxfordjournals.epirev.a018040 Khoder G, Muhammad JS, Mahmoud I, Soliman SSM, Burucoa C. Prevalence of Helicobacter pylori and Its Associated Factors among Healthy Asymptomatic Residents in the United Arab Emirates. Pathogens. Apr 1 2019;8(2)doi: 10.3390/pathogens8020044 Lee YC, Dore MP, Graham DY. Diagnosis and Treatment of Helicobacter pylori Infection. Annu Rev Med. Jan 27 2022;73:183–195. doi: 10.1146/annurev-med-042220-020814 Duck WM, Sobel J, Pruckler JM, et al. Antimicrobial resistance incidence and risk factors among Helicobacter pylori-infected persons, United States. Emerg Infect Dis. Jun 2004;10(6):1088–94. doi: 10.3201/eid1006.030744 Liu L, Huh JR, Shah K. Microbiota and the gut-brain-axis: Implications for new therapeutic design in the CNS. EBioMedicine. Mar 2022;77:103908. doi: 10.1016/j.ebiom.2022.103908 Baj J, Forma A, Flieger W, et al. Helicobacter pylori Infection and Extragastric Diseases-A Focus on the Central Nervous System. Cells. Aug 25 2021;10(9)doi: 10.3390/cells10092191 Pellicano R, Ianiro G, Fagoonee S, Settanni CR, Gasbarrini A. Review: Extragastric diseases and Helicobacter pylori. Helicobacter. Sep 2020;25 Suppl 1:e12741. doi: 10.1111/hel.12741 Heneka MT, Carson MJ, El Khoury J, et al. Neuroinflammation in Alzheimer's disease. Lancet Neurol. Apr 2015;14(4):388–405. doi: 10.1016/s1474-4422(15)70016-5 Qiu C, Kivipelto M, von Strauss E. Epidemiology of Alzheimer's disease: occurrence, determinants, and strategies toward intervention. Dialogues Clin Neurosci. 2009;11(2):111–28. doi: 10.31887/DCNS.2009.11.2/cqiu Silva MVF, Loures CMG, Alves LCV, de Souza LC, Borges KBG, Carvalho MDG. Alzheimer's disease: risk factors and potentially protective measures. J Biomed Sci. May 9 2019;26(1):33. doi: 10.1186/s12929-019-0524-y Zaidi SF, Ahmed K, Saeed SA, Khan U, Sugiyama T. Can Diet Modulate Helicobacter pylori-associated Gastric Pathogenesis? An Evidence-Based Analysis. Nutr Cancer. Oct 2017;69(7):979–989. doi: 10.1080/01635581.2017.1359310 Wang LS, Echeveste CE, Yu J, et al. Can Natural Products Suppress Resistant Helicobacter pylori to Fight Against Gastric Diseases in Humans? eFood . Feb 2020;1(1):53–60. doi: 10.2991/efood.k.200211.001 Huang YW, Echeveste CE, Oshima K, et al. Anti-colonic Inflammation by Black Raspberries through Regulating Toll-like Receptor-4 Signaling in Interlukin-10 Knockout Mice. J Cancer Prev. Jun 30 2020;25(2):119–125. doi: 10.15430/jcp.2020.25.2.119 Montrose DC, Horelik NA, Madigan JP, et al. Anti-inflammatory effects of freeze-dried black raspberry powder in ulcerative colitis. Carcinogenesis. Mar 2011;32(3):343–50. doi: 10.1093/carcin/bgq248 Wang LS, Kuo CT, Stoner K, et al. Dietary black raspberries modulate DNA methylation in dextran sodium sulfate (DSS)-induced ulcerative colitis. Carcinogenesis. Dec 2013;34(12):2842–50. doi: 10.1093/carcin/bgt310 Wang LS, Hecht SS, Carmella SG, et al. Anthocyanins in black raspberries prevent esophageal tumors in rats. Cancer Prev Res (Phila). Jan 2009;2(1):84–93. doi: 10.1158/1940-6207.Capr-08-0155 Pan P, Kang S, Wang Y, et al. Black Raspberries Enhance Natural Killer Cell Infiltration into the Colon and Suppress the Progression of Colorectal Cancer. Front Immunol. 2017;8:997. doi: 10.3389/fimmu.2017.00997 Murata-Kamiya N, Kurashima Y, Teishikata Y, et al. Helicobacter pylori CagA interacts with E-cadherin and deregulates the beta-catenin signal that promotes intestinal transdifferentiation in gastric epithelial cells. Oncogene . Jul 12 2007;26(32):4617-26. doi: 10.1038/sj.onc.1210251 Cover TL, Blanke SR. Helicobacter pylori VacA, a paradigm for toxin multifunctionality. Nat Rev Microbiol. Apr 2005;3(4):320–32. doi: 10.1038/nrmicro1095 Eftang LL, Esbensen Y, Tannæs TM, Bukholm IR, Bukholm G. Interleukin-8 is the single most up-regulated gene in whole genome profiling of H. pylori exposed gastric epithelial cells. BMC Microbiol. Jan 17 2012;12:9. doi: 10.1186/1471-2180-12-9 Crabtree JE, Peichl P, Wyatt JI, Stachl U, Lindley IJ. Gastric interleukin-8 and IgA IL-8 autoantibodies in Helicobacter pylori infection. Scand J Immunol. Jan 1993;37(1):65–70. doi: 10.1111/j.1365-3083.1993.tb01666.x Qu Y, Ma YH, Huang YY, et al. Blood biomarkers for the diagnosis of amnestic mild cognitive impairment and Alzheimer's disease: A systematic review and meta-analysis. Neurosci Biobehav Rev. Sep 2021;128:479–486. doi: 10.1016/j.neubiorev.2021.07.007 Jandhyala SM, Talukdar R, Subramanyam C, Vuyyuru H, Sasikala M, Nageshwar Reddy D. Role of the normal gut microbiota. World J Gastroenterol. 2015;21(29):8787–8803. doi: 10.3748/wjg.v21.i29.8787 Magne F, Gotteland M, Gauthier L, et al. The Firmicutes/Bacteroidetes Ratio: A Relevant Marker of Gut Dysbiosis in Obese Patients?. Nutrients . 2020;12(5):1474. Published 2020 May 19. doi: 10.3390/nu12051474 Qin J, Li R, Raes J, et al. A human gut microbial gene catalogue established by metagenomic sequencing. Nature. 2010;464(7285):59–65. doi: 10.1038/nature08821 Strandwitz P. Neurotransmitter modulation by the gut microbiota. Brain Res. 2018;1693(Pt B):128–133. doi: 10.1016/j.brainres.2018.03.015 Kesika P, Suganthy N, Sivamaruthi BS, Chaiyasut C. Role of gut-brain axis, gut microbial composition, and probiotic intervention in Alzheimer's disease. Life Sci. 2021;264:118627. doi: 10.1016/j.lfs.2020.118627 Rizzatti G, Lopetuso LR, Gibiino G, Binda C, Gasbarrini A. Proteobacteria: A Common Factor in Human Diseases. Biomed Res Int. 2017;2017:9351507. doi: 10.1155/2017/9351507 Hu X, Wang T, Jin F. Alzheimer's disease and gut microbiota. Sci China Life Sci. 2016;59(10):1006–1023. doi: 10.1007/s11427-016-5083-9 Belizário JE, Faintuch J. Microbiome and Gut Dysbiosis. Exp Suppl. 2018;109:459–476. doi: 10.1007/978-3-319-74932-7_13 Liu S, Gao J, Zhu M, Liu K, Zhang HL. Gut Microbiota and Dysbiosis in Alzheimer's Disease: Implications for Pathogenesis and Treatment. Mol Neurobiol. 2020;57(12):5026–5043. doi: 10.1007/s12035-020-02073-3 Brandscheid C, Schuck F, Reinhardt S, et al. Altered Gut Microbiome Composition and Tryptic Activity of the 5xFAD Alzheimer's Mouse Model. J Alzheimers Dis. 2017;56(2):775–788. doi: 10.3233/JAD-160926 Cryan JF, O'Riordan KJ, Cowan CSM, et al. The Microbiota-Gut-Brain Axis. Physiol Rev. 2019;99(4):1877–2013. doi: 10.1152/physrev.00018.2018 Holmes C, Cunningham C, Zotova E, Culliford D, Perry VH. Proinflammatory cytokines, sickness behavior, and Alzheimer disease. Neurology. 2011;77(3):212–218. doi: 10.1212/WNL.0b013e318225ae07 Goodman C, Lyon KN, Scotto A, et al. A High-Throughput Metabolic Microarray Assay Reveals Antibacterial Effects of Black and Red Raspberries and Blackberries against Helicobacter pylori Infection. Antibiotics (Basel) . 2021;10(7):845. Published 2021 Jul 12. doi: 10.3390/antibiotics10070845 Yu, Ji & Yu, Na-Jeong & Gim, Sung & Lee, Sujin & Kwon, Gyoo & Yuk, Hyun-Gyun. (2019). Antimicrobial effect of black raspberry (Rubus occidentalis, Bokbunja) extract against Escherichia coli and Staphylococcus aureus. Korean J. Food Preserv.. 26. 360–364. 10.11002/kjfp.2019.26.3.360 . Guerra-Valle M, Orellana-Palma P, Petzold G. Plant-Based Polyphenols: Anti- Helicobacter pylori Effect and Improvement of Gut Microbiota. Antioxidants (Basel) . 2022;11(1):109. Published 2022 Jan 4. doi: 10.3390/antiox11010109 Wu D, Cao M, Peng J, et al. The effect of trimethylamine N-oxide on Helicobacter pylori-induced changes of immunoinflammatory genes expression in gastric epithelial cells. Int Immunopharmacol. 2017;43:172–178. doi: 10.1016/j.intimp.2016.11.032 Albaret G, Sifré E, Floch P, et al. Alzheimer's Disease and Helicobacter pylori Infection: Inflammation from Stomach to Brain?. J Alzheimers Dis. 2020;73(2):801–809. doi: 10.3233/JAD-190496 Kountouras J. Helicobacter pylori: an intruder involved in conspiring glaucomatous neuropathy. Br J Ophthalmol. 2009;93(11):1413–1415. doi: 10.1136/bjo.2009.159046 Gupta V, Garg R. Probiotics. Indian J Med Microbiol. 2009;27(3):202–209. doi: 10.4103/0255-0857.53201 Barrett E, Ross RP, O'Toole PW, Fitzgerald GF, Stanton C. γ-Aminobutyric acid production by culturable bacteria from the human intestine [published correction appears in J Appl Microbiol. 2014;116(5):1384-6]. J Appl Microbiol . 2012;113(2):411–417. doi: 10.1111/j.1365-2672.2012.05344.x Solas M, Puerta E, Ramirez MJ. Treatment Options in Alzheimer´s Disease: The GABA Story. Curr Pharm Des. 2015;21(34):4960–4971. doi: 10.2174/1381612821666150914121149 Qian XH, Xie RY, Liu XL, Chen SD, Tang HD. Mechanisms of Short-Chain Fatty Acids Derived from Gut Microbiota in Alzheimer's Disease. Aging Dis. 2022;13(4):1252–1266. Published 2022 Jul 11. doi: 10.14336/AD.2021.1215 Wenzel TJ, Gates EJ, Ranger AL, Klegeris A. Short-chain fatty acids (SCFAs) alone or in combination regulate select immune functions of microglia-like cells. Mol Cell Neurosci. 2020;105:103493. doi: 10.1016/j.mcn.2020.103493 Chen Y, Xu J, Chen Y. Regulation of Neurotransmitters by the Gut Microbiota and Effects on Cognition in Neurological Disorders. Nutrients . 2021;13(6):2099. Published 2021 Jun 19. doi: 10.3390/nu13062099 Strandwitz P, Kim KH, Terekhova D, et al. GABA-modulating bacteria of the human gut microbiota. Nat Microbiol. 2019;4(3):396–403. doi: 10.1038/s41564-018-0307-3 Blaak EE, Canfora EE, Theis S, et al. Short chain fatty acids in human gut and metabolic health. Benef Microbes. 2020;11(5):411–455. doi: 10.3920/BM2020.0057 Zhou K. Strategies to promote abundance of Akkermansia muciniphila, an emerging probiotics in the gut, evidence from dietary intervention studies. J Funct Foods. 2017;33:194–201. doi: 10.1016/j.jff.2017.03.045 Macchione IG, Lopetuso LR, Ianiro G, et al. Akkermansia muciniphila: key player in metabolic and gastrointestinal disorders. Eur Rev Med Pharmacol Sci. 2019;23(18):8075–8083. doi: 10.26355/eurrev_201909_19024 Rodrigues VF, Elias-Oliveira J, Pereira ÍS, et al. Akkermansia muciniphila and Gut Immune System: A Good Friendship That Attenuates Inflammatory Bowel Disease, Obesity, and Diabetes. Front Immunol. 2022;13:934695. Published 2022 Jul 7. doi: 10.3389/fimmu.2022.934695 Cani PD, Depommier C, Derrien M, Everard A, de Vos WM. Akkermansia muciniphila: paradigm for next-generation beneficial microorganisms [published correction appears in Nat Rev Gastroenterol Hepatol. 2022;:]. Nat Rev Gastroenterol Hepatol. 2022;19(10):625–637. doi: 10.1038/s41575-022-00631-9 Roopchand DE, Carmody RN, Kuhn P, et al. Dietary Polyphenols Promote Growth of the Gut Bacterium Akkermansia muciniphila and Attenuate High-Fat Diet-Induced Metabolic Syndrome. Diabetes. 2015;64(8):2847–2858. doi: 10.2337/db14-1916 Anhê FF, Roy D, Pilon G, et al. A polyphenol-rich cranberry extract protects from diet-induced obesity, insulin resistance and intestinal inflammation in association with increased Akkermansia spp. population in the gut microbiota of mice. Gut. 2015;64(6):872–883. doi: 10.1136/gutjnl-2014-307142 Mezhibovsky E, Wu Y, Bawagan FG, Tveter KM, Szeto S, Roopchand D. Impact of grape polyphenols on Akkermansia muciniphila and the gut barrier. AIMS Microbiol. 2022;8(4):544–565. Published 2022 Dec 22. doi: 10.3934/microbiol.2022035 McLeod A, Penalver Bernabe B, Xia Y, et al. Comparing the gut microbiome of obese, African American, older adults with and without mild cognitive impairment. PLoS One. 2023;18(2):e0280211. Published 2023 Feb 24. doi: 10.1371/journal.pone.0280211 Ahl S, Guenther M, Zhao S, et al. Adiponectin Levels Differentiate Metabolically Healthy vs Unhealthy Among Obese and Nonobese White Individuals. J Clin Endocrinol Metab. Nov 2015;100(11):4172–80. doi: 10.1210/jc.2015-2765 Chan WSA, Liew CF, Theng CTS, Oon HH. Serum Adiponectin Levels and Their Association With Cardiometabolic Risk Factors in Patients With Psoriasis. Cureus. May 15 2020;12(5):e8128. doi: 10.7759/cureus.8128 Additional Declarations (Not answered) Supplementary Files SupplFigures.pptx SupplTables.docx Cite Share Download PDF Status: Published Journal Publication published 12 Feb, 2025 Read the published version in npj Science of Food → Version 1 posted Editorial decision: revise 16 Aug, 2024 Review # 2 received at journal 13 Aug, 2024 Reviewer # 2 agreed at journal 13 Aug, 2024 Review # 1 received at journal 30 Apr, 2024 Reviewer # 1 agreed at journal 17 Apr, 2024 Reviewers invited by journal 06 Feb, 2024 Submission checks completed at journal 30 Jan, 2024 First submitted to journal 26 Jan, 2024 Editor assigned by journal 26 Jan, 2024 You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-3899398","acceptedTermsAndConditions":true,"allowDirectSubmit":false,"archivedVersions":[],"articleType":"Article","associatedPublications":[],"authors":[{"id":271469781,"identity":"61007fdb-6fc2-4a0b-89ed-29c68566e18d","order_by":0,"name":"Chin-Kun Wang","email":"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAZAAAAAyAQMAAABI0h/eAAAABlBMVEX///8AAABVwtN+AAAACXBIWXMAAA7EAAAOxAGVKw4bAAAAqUlEQVRIiWNgGAWjYFACNsYHUJYB0VqYYUqBdAJxWtgkSNNicPxYWsWPP9sSG9ibt0kw/jhMhJYzacdu9rbdTmzgOVYmwZBAhBazG+xttxkbgFokcsyAWm4Tp6WY4Q9Qi/wborWwHWNmYAPZwkOkFvszacmSQL8Yt/GkFVskpP0nrEWy/Zjhhx9/bsv2sx/eeOODTRphLXDABiISSNAwCkbBKBgFowAPAABE5DlLEztipgAAAABJRU5ErkJggg==","orcid":"https://orcid.org/0000-0001-5371-7847","institution":"Chung Shan Medical University","correspondingAuthor":true,"prefix":"","firstName":"Chin-Kun","middleName":"","lastName":"Wang","suffix":""},{"id":271469782,"identity":"9070a633-2310-40b7-86cf-bcdaa2b74b81","order_by":1,"name":"Yohanes Tandoro","email":"","orcid":"","institution":"Chung Shan Medical University","correspondingAuthor":false,"prefix":"","firstName":"Yohanes","middleName":"","lastName":"Tandoro","suffix":""},{"id":271469783,"identity":"0bc0cd6c-31d6-439b-8c16-6165c4aaa040","order_by":2,"name":"Hui-Fang Chiu","email":"","orcid":"","institution":"Ministry of Health \u0026 Well-being","correspondingAuthor":false,"prefix":"","firstName":"Hui-Fang","middleName":"","lastName":"Chiu","suffix":""},{"id":271469784,"identity":"937c7ab0-ccbb-46e1-8b10-4ccf958a58f7","order_by":3,"name":"Chei-Ling Tan","email":"","orcid":"","institution":"Chung Shan Medical University","correspondingAuthor":false,"prefix":"","firstName":"Chei-Ling","middleName":"","lastName":"Tan","suffix":""},{"id":271469785,"identity":"ea0f7bc4-b8ca-43e8-b0ef-2ce8a5ae91c5","order_by":4,"name":"Ming-Hong Hsieh","email":"","orcid":"","institution":"Chung Shan Medical University","correspondingAuthor":false,"prefix":"","firstName":"Ming-Hong","middleName":"","lastName":"Hsieh","suffix":""},{"id":271469786,"identity":"577a8777-e10f-4838-a72c-9688af000b37","order_by":5,"name":"Yi-Wen Huang","email":"","orcid":"","institution":"Medical College of Wisconsin","correspondingAuthor":false,"prefix":"","firstName":"Yi-Wen","middleName":"","lastName":"Huang","suffix":""},{"id":271469787,"identity":"5000163e-5f14-4740-8a08-3539bac0e9a3","order_by":6,"name":"Jianhua Yu","email":"","orcid":"","institution":"City of Hope National Medical Center","correspondingAuthor":false,"prefix":"","firstName":"Jianhua","middleName":"","lastName":"Yu","suffix":""},{"id":271469788,"identity":"46c1bb3c-007c-41ee-a17d-84f946fda574","order_by":7,"name":"Li-Shu Wang","email":"","orcid":"","institution":"City of Hope National Medical Center","correspondingAuthor":false,"prefix":"","firstName":"Li-Shu","middleName":"","lastName":"Wang","suffix":""},{"id":271469789,"identity":"89ed8824-0a59-4672-8b1d-025484ec31fc","order_by":8,"name":"Chi-Ho Chan","email":"","orcid":"https://orcid.org/0000-0003-4872-5791","institution":"Chung Shan Medical University","correspondingAuthor":false,"prefix":"","firstName":"Chi-Ho","middleName":"","lastName":"Chan","suffix":""}],"badges":[],"createdAt":"2024-01-26 08:19:31","currentVersionCode":1,"declarations":"","doi":"10.21203/rs.3.rs-3899398/v1","doiUrl":"https://doi.org/10.21203/rs.3.rs-3899398/v1","draftVersion":[],"editorialEvents":[{"content":"https://doi.org/10.1038/s41538-024-00356-w","type":"published","date":"2025-02-12T05:00:00+00:00"}],"editorialNote":"","failedWorkflow":false,"files":[{"id":50925680,"identity":"6c9494f8-bbfa-42b1-8f00-153986b08f69","added_by":"auto","created_at":"2024-02-09 17:08:16","extension":"png","order_by":1,"title":"Figure 1","display":"","copyAsset":false,"role":"figure","size":374688,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eBRB intervention dramatically improved cognitive functions in patients with mild dementia due to AD. \u003c/strong\u003e(A) At baseline, BRB and placebo had clinical dementia rating (CDR) scores at 0.5. 8-week BRBs significantly moved CDR to zero, but the placebo group remained the same. (B) BRB crude extract rescued Aβ-induced cytotoxicity in HT22 cells. * p\u0026lt;0.05: compared with untreated\u003c/p\u003e","description":"","filename":"floatimage1.png","url":"https://assets-eu.researchsquare.com/files/rs-3899398/v1/a32d5349313aec140c3d50a5.png"},{"id":50927512,"identity":"4137ef52-87b0-4c36-adf8-057f80a1c8b6","added_by":"auto","created_at":"2024-02-09 17:16:16","extension":"jpeg","order_by":2,"title":"Figure 2","display":"","copyAsset":false,"role":"figure","size":260842,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eBRB consumption altered gut microbiome population in patients with mild dementia due to AD. (A) Stool \u003c/strong\u003e\u003cem\u003e\u003cstrong\u003eProteobacteria \u003c/strong\u003e\u003c/em\u003e\u003cstrong\u003eanalysis. (B) Stool pathogen analysis. (C) Stool probiotics analysis. (D) Stool \u003c/strong\u003e\u003cem\u003e\u003cstrong\u003eAkkermansia muciniphilla\u003c/strong\u003e\u003c/em\u003e\u003cstrong\u003eanalysis.\u003c/strong\u003e\u003c/p\u003e","description":"","filename":"floatimage2.jpeg","url":"https://assets-eu.researchsquare.com/files/rs-3899398/v1/a79233ffba257a92c545faf6.jpeg"},{"id":50925684,"identity":"8febf5c6-1ca0-4247-8606-765f2e72edd6","added_by":"auto","created_at":"2024-02-09 17:08:16","extension":"jpeg","order_by":3,"title":"Figure 3","display":"","copyAsset":false,"role":"figure","size":326533,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eBRB extracts suppressed \u003c/strong\u003e\u003cem\u003e\u003cstrong\u003eH. pylori \u003c/strong\u003e\u003c/em\u003e\u003cstrong\u003einfection in AGS cells and lipid accumulation in 3T3-L1 mature adipocytes. \u003c/strong\u003eAGS cells were treated with crude extract and gelatin-treated crude extract, and cell viability (A), \u003cem\u003eH. pylori \u003c/em\u003eadhesion (B), CagA and VagA protein expressions (C), and IL-8 level (D) were evaluated. (E) Three BRB extracts, crude extract, gelatin-treated crude extract, and tannins fraction, enhanced cell viability of 3T3-L1 pre-adipocytes and (F) decreased lipid accumulation in 3T3-L1 mature adipocytes. (A) +: 50 ,++: 500 ug/mL, (B) +: 50 ,++: 500 ug/mL, (C) +: 50, 100, 250, 500, 1000 ug/mL, (D)+: 50 ,++: 500 ug/mL. * p\u0026lt;0.05: compared with untreated, \u003csup\u003e$\u003c/sup\u003ep\u0026lt;0.05: compared with \u003cem\u003eH. pylori \u003c/em\u003etreated\u003c/p\u003e","description":"","filename":"floatimage3.jpeg","url":"https://assets-eu.researchsquare.com/files/rs-3899398/v1/6a3ac69a885f5db63cbad1ab.jpeg"},{"id":76183698,"identity":"c4729e5b-dc0c-44a3-9b4c-eb8ded71b7ba","added_by":"auto","created_at":"2025-02-13 08:07:53","extension":"pdf","order_by":0,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":2256808,"visible":true,"origin":"","legend":"","description":"","filename":"manuscript.pdf","url":"https://assets-eu.researchsquare.com/files/rs-3899398/v1/ff6dc500-e2c2-4760-92e5-05787f04b134.pdf"},{"id":50925681,"identity":"45d8d326-c1b7-4c5c-8988-cdc83427aab7","added_by":"auto","created_at":"2024-02-09 17:08:16","extension":"pptx","order_by":2,"title":"","display":"","copyAsset":false,"role":"supplement","size":42985,"visible":true,"origin":"","legend":"","description":"","filename":"SupplFigures.pptx","url":"https://assets-eu.researchsquare.com/files/rs-3899398/v1/51ecb8a171af294bf10195af.pptx"},{"id":50925683,"identity":"6fc4fbd0-93d9-4fc7-8276-ee4efa59095b","added_by":"auto","created_at":"2024-02-09 17:08:16","extension":"docx","order_by":3,"title":"","display":"","copyAsset":false,"role":"supplement","size":27108,"visible":true,"origin":"","legend":"","description":"","filename":"SupplTables.docx","url":"https://assets-eu.researchsquare.com/files/rs-3899398/v1/88fd87517e1b7d4a6203f212.docx"}],"financialInterests":"(Not answered)","formattedTitle":"Dietary Black Raspberry Supplementation as Natural Polyphenol Source Against Mild Dementia Patients with Overweight and Helicobacter pylori Infection","fulltext":[{"header":"Introduction","content":"\u003cp\u003eAlzheimer's disease (AD) is a neurodegenerative condition associated with dementia, memory and cognition impairment, and behavioral changes. AD is estimated to affect over 40\u0026nbsp;million people globally, with the prevalence of the condition anticipated to increase over the next several decades, especially in low socioeconomic status countries\u003csup\u003e1,2\u003c/sup\u003e. The pathophysiology of AD is not clearly understood, but genetic and environmental risk factors appear to contribute to the condition.\u003c/p\u003e \u003cp\u003eOne condition potentially related to AD development is infection with the bacterium \u003cem\u003eHelicobacter pylori\u003c/em\u003e. AD affects nearly 4.5\u0026nbsp;billion people worldwide. This condition disproportionately affects those from disadvantaged, low socioeconomic status, or immigrant backgrounds. Lack of adequate sanitation and nutrition are among the environmental risk factors for developing infection\u003csup\u003e3\u0026ndash;5\u003c/sup\u003e. \u003cem\u003eH. pylori\u003c/em\u003e infection frequently presents as general dyspepsia. Still, it has the potential to lead to more severe conditions such as peptic ulcer disease, mucosa-associated lymphoid tissue lymphoma, and gastric adenocarcinoma, which makes it imperative to diagnose and treat \u003cem\u003eH. pylori\u003c/em\u003e infection, given its significant global prevalence\u003csup\u003e6\u003c/sup\u003e. \u003cem\u003eH. pylori\u003c/em\u003e has been implicated in AD via the gut-brain axis (GBA), a network connecting the gastrointestinal and central nervous systems via signals such as metabolites from gut microbiota, gastrointestinal hormones, and immunologic modulators\u003csup\u003e7\u003c/sup\u003e. As bacteria such as \u003cem\u003eH. pylori\u003c/em\u003e infect the gastrointestinal tract, they may affect immune and metabolic signaling within the GBA and thereby lead to CNS changes. Recent studies indicate a possible link between AD and \u003cem\u003eH. pylori\u003c/em\u003e infection, evidenced by factors such as increased anti-\u003cem\u003eH. pylori\u003c/em\u003e IgG in AD patients\u003csup\u003e8,9\u003c/sup\u003e. However, the research on \u003cem\u003eH. pylori\u003c/em\u003e in concurrence with AD remains inconclusive.\u003c/p\u003e \u003cp\u003eAnother gastrointestinal factor implicated in AD development is obesity. As with \u003cem\u003eH. pylori\u003c/em\u003e infection, obesity may be related to AD via the gut-brain axis, especially when considering immunological factors. For instance, obesity is associated with increased susceptibility to bacterial infection, reduction in gut microbiome diversity, and subsequent pro-inflammatory profiles, a cascade that may increase the risk of developing AD\u003csup\u003e10\u003c/sup\u003e. Interestingly, several studies demonstrate that this risk appears to be highest when obesity is present in middle age; the reason for this remains unclear\u003csup\u003e11,12\u003c/sup\u003e.\u003c/p\u003e \u003cp\u003eTogether, \u003cem\u003eH. pylori\u003c/em\u003e infection, obesity, and AD form a triad of epidemiologically overall conditions that may be linked via immunological and metabolic pathways of the GBA. However, the literature remains inconclusive regarding definitive relationships, and no previous studies have attempted to connect all three of these conditions. This merits exploration regarding treatments that can target these pathways, providing more favorable inflammatory profiles and hopefully reducing AD incidence. One potential treatment route may be a dietary modification, which has been demonstrated to affect both obesity and \u003cem\u003eH. pylori\u003c/em\u003e infection by modulating the gut microbiome and inflammatory cascades\u003csup\u003e13,14\u003c/sup\u003e. Our previous research has highlighted the role of black raspberries (BRBs) in autoimmune and malignant conditions and found that in certain situations, BRBs and their metabolic components suppress pro-inflammatory markers and foster gut microbiota with less inflammatory profiles. For instance, in a murine model of ulcerative colitis, diet supplementation with BRBs was associated with reduced levels of phospho-IκBα, cyclooxygenase-2 (COX-2), toll-like receptor and prostaglandin E₂, all of which are associated with inflammation\u003csup\u003e15\u0026ndash;19\u003c/sup\u003e. It is possible that the gastrointestinal effects demonstrated to result from BRBs may extend to conditions such as obesity and \u003cem\u003eH. pylori\u003c/em\u003e, both of which are also strongly associated with inflammation.\u003c/p\u003e \u003cp\u003eThe purpose of this study was to determine whether supplementation of diet with BRBs has a meaningful effect on the gastrointestinal conditions of \u003cem\u003eH. pylori\u003c/em\u003e infection and overweight and the development of AD in a clinical trial setting.\u003c/p\u003e"},{"header":"Methods","content":"\u003cdiv id=\"Sec3\" class=\"Section2\"\u003e \u003ch2\u003eClinical trial\u003c/h2\u003e \u003cp\u003eThe clinical trial protocol was approved by the IRB at Chung Shan Medical University, Taiwan (protocol number CS2-21103, Title: The improvement of black raspberry in obese and mild AZ patients infected with \u003cem\u003eH. pylori\u003c/em\u003e). Inclusion criteria for this study were as follows: BMI\u0026thinsp;\u0026ge;\u0026thinsp;27; waist circumference for men\u0026thinsp;\u0026ge;\u0026thinsp;90 cm, women\u0026thinsp;\u0026ge;\u0026thinsp;80 cm; body fat for men\u0026thinsp;\u0026ge;\u0026thinsp;25%, women 30%; a \u003csup\u003e13\u003c/sup\u003eC urea breath test (UBT) test value\u0026thinsp;\u0026gt;\u0026thinsp;10% indicating \u003cem\u003eH. pylori\u003c/em\u003e positivity; and clinical dementia rating (CDR)\u0026thinsp;=\u0026thinsp;0.5. Exclusion criteria were as follows: BMI\u0026thinsp;\u0026lt;\u0026thinsp;27; severe chronic disease (liver disease, cardiovascular disease, kidney disease); taking medications known to affect lipid metabolism or possess anti-inflammatory effects; gastrointestinal disorder; surgery; alcohol abuse; smoking; pregnant or lactating; taking berry-related supplementation or having known allergies or hypersensitivity to berries, including BRBs; taking antibiotics/ corticosteroids in the last 4 weeks; taking NSAIDs or COX-2 inhibitors due to external clinical conditions; and/or prior history of \u003cem\u003eH. pylori\u003c/em\u003e infection treated with triple therapy.\u003c/p\u003e \u003cp\u003eIn total, 21 subjects were recruited for the study; 11 (8 males and 3 females) in the berry group and 10 (4 males and 6 females) in the placebo group. Subjects were aged 60\u0026ndash;85 years old. Those in the BRB group received 25 g of black raspberry powder dissolved in 240 mL of water twice a day, once after breakfast and once after dinner, resulting in total consumption of 50 g of black raspberry powder per day. Subjects in the placebo group received 25 g of dextrin twice per day, administered in the same way as the black raspberry powder to a total of 50 g of dextrin per day. Each 50 g of black raspberry powder was estimated to contain (mean\u0026thinsp;\u0026plusmn;\u0026thinsp;SD) 1926.50\u0026thinsp;\u0026plusmn;\u0026thinsp;547.00 mg/g of phenols, 336.50\u0026thinsp;\u0026plusmn;\u0026thinsp;11.00 mg/g of flavonoids, 1101.50\u0026thinsp;\u0026plusmn;\u0026thinsp;51.00 mg/g of anthocyanins, 5581.00\u0026thinsp;\u0026plusmn;\u0026thinsp;715.00 mg/g of condensed tannins, and 10.49 g of fiber (\u003cb\u003eSupplementary Table\u0026nbsp;1\u003c/b\u003e).\u003c/p\u003e \u003cp\u003eThe study was conducted over 10 weeks, consisting of an 8-week intervention period and a 2-week follow-up. At week 0, anthropometric measurements were taken of weight, height, BMI, waist circumference, hip circumference, blood pressure, body fat, and triceps skinfold thickness. Patients were asked to maintain their regular diets while on trial, and they kept a 3-day dietary record consisting of 2 weekdays and 1 weekend day. Blood sampling was also taken to assess lipid profile, cytokine levels, inflammatory markers, antioxidant index, thyroid function, liver function, kidney function, and blood chemistry. A \u003csup\u003e13\u003c/sup\u003eC UBT, fecal sampling, and CDR were also performed at week 0. At week 2, anthropometric measurements and dietary recall were repeated. At week 4, anthropometric measurements, dietary recall, and blood sampling were performed. At week 6, anthropometric measurements and dietary recall were performed. At week 8, anthropometric measurements, dietary recall, blood and fecal sampling, and \u003csup\u003e13\u003c/sup\u003eC UBT and CDR were performed. At the week 10 follow-up, anthropometric measurements, dietary recall, and blood sampling were performed.\u003c/p\u003e \u003cp\u003eFecal Sample Analysis\u003c/p\u003e \u003cp\u003eFecal samples from the subjects consumed BRBs were collected at baseline and end of the intervention. The fecal sample is prepared in the Colon Heal bacterial detection kit (Aging and Disease Prevention Research Center, Fooyin University, Kaohsiung, Taiwan) following manufacturer's instruction. 16S library pool was performed using Illumina MiSeq system library preparation instruction. Forward (F)/reverse (R) primers (F: 5'-TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGCCTACGGGNGGCWGCAG-3\u0026rsquo;/R: 5'-GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGGACTACHVGGGTATCTAATCC-3') with overhang sequence were used for metagenome analysis to generate Illumina 16S library by two-step polymerase chain reaction. 16S libraries generated were pooled and sequenced using MiSeq with MiSeq V3 reagent kits and analyzed with MiSeq Reporter Software (MSR). Classification of the result is based on the Greengenes database (\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttp://greengenes.lbl.gov/\u003c/span\u003e\u003cspan address=\"http://greengenes.lbl.gov/\" targettype=\"URL\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e). The mean of relative abundance was compared at the phylum, genus, and species levels.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec4\" class=\"Section2\"\u003e \u003ch2\u003ePreparations of different BRB extracts\u003c/h2\u003e \u003cp\u003eProcedures to prepare BRB crude extract, crude extract treated with gelatin, and tannins fraction are shown in \u003cb\u003eSupplemental Fig.\u0026nbsp;1\u003c/b\u003e. Phenolic contents in different BRB extracts are listed in \u003cb\u003eSupplemental Table\u0026nbsp;1\u003c/b\u003e.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec5\" class=\"Section2\"\u003e \u003ch2\u003eAGS cell model\u003c/h2\u003e \u003cp\u003eHuman gastric adenocarcinoma cell culture (AGS cell) was purchased from American Type Culture Collection (ATCC) and cultured in F12 (Ham\u0026rsquo;s media Kaighn Modification, Cytiva) medium containing 10% of Fetal Bovine Serum 37 \u003csup\u003eo\u003c/sup\u003eC humidified incubator with 5% CO2.\u003c/p\u003e \u003cp\u003eCell viability\u003c/p\u003e \u003cp\u003eThe cell viability was evaluated using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) method. AGS cells (2 \u0026times; 10\u003csup\u003e5\u003c/sup\u003e /mL) were seeded into a 96-well plate and incubated overnight. Increasing concentrations of BRB crude and gelatin treated crude extracts (0, 50, 100, 250, 500, 1000 \u0026micro;g/mL in serum-free medium with 0.05 Dimethyl Sulfoxide (DMSO)) or \u003cem\u003eH. pylori\u003c/em\u003e (OD\u003csub\u003e600\u003c/sub\u003e 0.3 (1 x 10\u003csup\u003e8\u003c/sup\u003e CFU/ mL)) were co-cultured with AGS cells and incubated at 37\u0026deg;C for 24 hours. After 24 hours, the medium was removed and changed with 100 \u0026micro;L (0.5 mg/mL) of MTT in phosphate-buffered saline (1X PBS) and cultured at 37\u0026deg;C for 3 hours. Finally, the cells were mixed with 100 \u0026micro;L DMSO and shaken for 10 min (to dissolve formazan crystals), and the absorbance was measured using a microplate reader at 570 nm. The blank wells were prepared with no cells and positive control wells were 50 \u0026micro;g/mL Amoxicillin. The cell viability (%) was calculated with the following equation:\u003c/p\u003e \u003cp\u003eCell viability (%)\u0026thinsp;=\u0026thinsp;Absorbance (Sample \u0026ndash; Blank)/ Absorbance (Control \u0026ndash; Blank) x 100%\u003c/p\u003e \u003cp\u003e \u003cem\u003eH. pylori\u003c/em\u003e Adhesion\u003c/p\u003e \u003cp\u003eAGS cells were seeded in 24-well plates and incubated overnight. Increasing concentrations of BRB crude and gelatin treated crude extract (0, 50, 100, 250, 500, 1000 \u0026micro;g/mL) or amoxicillin (0.05 mg/mL) and \u003cem\u003eH. pylori\u003c/em\u003e suspension were added to each well and incubated for 6 hours in a humidified CO2 incubator. The nonadherent bacteria were washed off with 1X PBS solution. The final suspension was collected after 6 hours of incubation to quantify the bacterial viability in the urease reagent and read at 560 and 600 nm. Adherent bacteria were evaluated with urease reagent (3 mM PBS pH 5.8; 2% urea and 4 \u0026micro;g/mL phenol red, pH 5.0) and read absorbance at 560 nm and calculated by the formula:\u003c/p\u003e \u003cp\u003eAnti-adhesive activity (%) = (control absorbance\u0026thinsp;\u0026minus;\u0026thinsp;sample absorbance) ∕ control absorbance \u0026times; 100%\u003c/p\u003e \u003cp\u003eCagA, VacA western blot\u003c/p\u003e \u003cp\u003eAnalysis of CagA and VacA expression detected using western blot analysis. AGS cells were seeded in 10 cm dish plates and incubated overnight. Increasing concentrations of BRB crude and gelatin treated crude extract (0, 0.05, 0.1, 0.25, 0.5, and 1 mg/mL) or amoxicillin (0.05 mg/mL) and \u003cem\u003eH. pylori\u003c/em\u003e suspension were added to each plate and incubated for 6 hours. All cells were collected and lysed using ice-cold lysis buffer, and cell protein was collected after centrifugation (3000 RPM, 10 minutes, 4\u003csup\u003eo\u003c/sup\u003eC). Cell proteins were separated in 8% polyacrylamide gel and blotted to polyvinylidene difluoride membrane (PVDF). The membrane was blocked in 5% skim milk in TBS buffer containing 0.2% Tween-20. The membrane was incubated with anti-beta actin monoclonal antibody (SC-47778, Santa Cruz Biotechnology, USA), anti-CagA monoclonal antibody (SC-28368, Santa Cruz Biotechnology, USA) and anti-VacA monoclonal antibody (SC-32746, Santa Cruz Biotechnology, USA) overnight at 4\u003csup\u003eo\u003c/sup\u003eC. After the removal of the primary antibody, the membrane was soaked in HRP-conjugated anti-mouse secondary antibody (Invitrogen, Thermo Fischer, USA) for 1 hour at room temperature. Reacted band of the targeted protein was revealed using enhanced chemiluminescence (ECL) using ECL commercial kit (G-Biosciences, USA).\u003c/p\u003e \u003cp\u003eIL-8 secretion\u003c/p\u003e \u003cp\u003eIL-8 content was determined using a commercialized IL-8 ELISA kit (Biolegend, California, USA) by following the manufacture's protocol. Each sample was tested in triplicate\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec6\" class=\"Section2\"\u003e \u003ch2\u003e3T3-L1 pre-adipocyte and mature 3T3-L1 adipocytes\u003c/h2\u003e \u003cp\u003e3T3-L1 was purchased from American Type Culture Collection (ATCC) and cultured in DMEM (Gibco) medium containing 10% bovine calf serum and differentiated into mature adipocytes by DMEM containing 0.5 mM IBMX (3-isobutyl-1-methylxanthine), 1 mM DEXA and 10 mg/mL insulin at 37 \u003csup\u003eo\u003c/sup\u003eC humidified incubator with 5% CO2.\u003c/p\u003e \u003cp\u003eCell viability of 3T3-L1 pre-adipocytes\u003c/p\u003e \u003cp\u003eThe cell viability was evaluated using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) method. 3T3-L1 pre-adipocytes were seeded into a 96-well plate and incubated overnight. Increasing BRB crude extract concentration, gelatin treated crude extract, and tannin fraction (0, 0.1, 0.5, 1, 2, 5, 10, 15, and 20 mg/mL) were added and incubated at 37\u0026deg;C for 24 hours. After 24 hours, the medium was removed and changed with 100 \u0026micro;L (0.5 mg/mL) of MTT in phosphate-buffered saline (1X PBS) and cultured at 37\u0026deg;C for 4 hours. Finally, the cells were mixed with 100 \u0026micro;L DMSO and shaken for 10 min (to dissolve formazan crystals), and the absorbance was measured using a microplate reader at 570 nm. The blank wells were no cells. The cell viability (%) was calculated with the following equation:\u003c/p\u003e \u003cp\u003eCell viability (%)\u0026thinsp;=\u0026thinsp;Absorbance (Sample \u0026ndash; Blank)/ Absorbance (Control \u0026ndash; Blank) x 100%\u003c/p\u003e \u003cp\u003eOil-red staining in mature 3T3-L1 adipocytes for lipid accumulation\u003c/p\u003e \u003cp\u003eMature adipocytes in 24 wells were washed twice with PBS and fixed using 10% formaldehyde solution for 1 hour. After 1 hour, cells were washed twice using PBS, and 0.5% oil red solution (in isopropanol) were added and incubated for 15 minutes to stain the lipid droplets. Cells were washed with dd H\u003csub\u003e2\u003c/sub\u003eO to remove unbound oil red. Isopropanol was added to dissolve the oil red and shake for 10 minutes. 100 \u0026micro;L of the solution was transferred to 96 wells, and read absorbance at 490 nm and lipid accumulation were calculated with the following equation:\u003c/p\u003e \u003cp\u003eLipid accumulation (%)\u0026thinsp;=\u0026thinsp;Absorbance (Sample)/ Absorbance (Control) x 100%\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec7\" class=\"Section2\"\u003e \u003ch2\u003eStatistical analysis\u003c/h2\u003e \u003cp\u003eThe sample size was calculated to assess difference among groups (α: 0.05) with 5% reduction of UBT value using 95% confidence interval and 80% power (1-β) and according to calculation each group need at least 6 subjects and considering dropout rate of 20%, 10 subjects in each group is used. Repeated measure ANOVA and chi-squared test is used to assess difference within the group (intervention vs baseline) as appropriate. Results obtained from cells were analyzed with one-way ANOVA of SPSS (version 26, SPSS Inc). Significance difference is identified with \u003cem\u003ep\u003c/em\u003e\u0026thinsp;\u0026lt;\u0026thinsp;0.05\u003c/p\u003e \u003c/div\u003e"},{"header":"Results","content":"\u003cp\u003e \u003cb\u003eBRB consumption improves cognitive function in patients with mild dementia due to Alzheimer's disease associated with decreased inflammation and oxidative stress.\u003c/b\u003e \u003c/p\u003e \u003cp\u003eWe conducted a placebo-controlled clinical trial in patients with mild clinical dementia due to AD who also had \u003cem\u003eH. pylori\u003c/em\u003e infection and were overweight (aged 60\u0026ndash;85 years old.). The baseline patient demographics show that age, Clinical Dementia Rating (CDR), body mass index (BMI), and urea breath test (UBT) are statistically the same (Table\u0026nbsp;\u003cspan refid=\"Tab1\" class=\"InternalRef\"\u003e1\u003c/span\u003e). Patients were randomized to either BRB or placebo group. BRB group consumed 8-week BRBs (25g, twice a day, morning and evening, n\u0026thinsp;=\u0026thinsp;11, 8 males and 3 females). The placebo group consumed a placebo powder (25g, twice a day, morning and evening, n\u0026thinsp;=\u0026thinsp;10, 4 males and 6 females). After the 8-week intervention, all patients were followed up for 2 weeks.\u003c/p\u003e \u003cp\u003e \u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab1\" border=\"1\"\u003e \u003ccaption language=\"En\"\u003e \u003cdiv class=\"CaptionNumber\"\u003eTable 1\u003c/div\u003e \u003cdiv class=\"CaptionContent\"\u003e \u003cp\u003eBaseline patient demographics\u003c/p\u003e \u003c/div\u003e \u003c/caption\u003e \u003ccolgroup cols=\"4\"\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c1\" colnum=\"1\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c2\" colnum=\"2\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c3\" colnum=\"3\"\u003e\u003c/div\u003e \u003cdiv align=\"char\" char=\".\" class=\"colspec\" colname=\"c4\" colnum=\"4\"\u003e\u003c/div\u003e \u003cthead\u003e \u003ctr\u003e \u003cth align=\"left\" colname=\"c1\"\u003e\u0026nbsp;\u003c/th\u003e \u003cth align=\"left\" colname=\"c2\"\u003e \u003cp\u003ePlacebo\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c3\"\u003e \u003cp\u003eBRBs\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c4\"\u003e \u003cp\u003e\u003cem\u003ep\u003c/em\u003e value\u003c/p\u003e \u003c/th\u003e \u003c/tr\u003e \u003c/thead\u003e \u003ctbody\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eAge\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e78.9\u0026thinsp;\u0026plusmn;\u0026thinsp;3.0\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e77.5\u0026thinsp;\u0026plusmn;\u0026thinsp;3.0\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e0.32\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eGender\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eMale\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e4\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e8\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e0.20\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eFemale\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e6\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e3\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eBMI\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e28.5\u0026thinsp;\u0026plusmn;\u0026thinsp;0.9\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e29.5\u0026thinsp;\u0026plusmn;\u0026thinsp;1.9\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e0.14\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eUBT\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e23.0\u0026thinsp;\u0026plusmn;\u0026thinsp;1.8\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e22.1\u0026thinsp;\u0026plusmn;\u0026thinsp;4.2\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e0.50\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eCDR\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e0.5\u0026thinsp;\u0026plusmn;\u0026thinsp;0.0\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e0.5\u0026thinsp;\u0026plusmn;\u0026thinsp;0.0\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e1.00\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003c/tbody\u003e \u003c/colgroup\u003e \u003ctfoot\u003e \u003ctr\u003e\u003ctd colspan=\"4\"\u003eThe results are expressed as mean\u0026thinsp;\u0026plusmn;\u0026thinsp;SD.\u003c/td\u003e\u003c/tr\u003e \u003ctr\u003e\u003ctd colspan=\"4\"\u003eBMI: body mass index; UBT: urea breath test; CDR: clinical dementia rating\u003c/td\u003e\u003c/tr\u003e \u003c/tfoot\u003e \u003c/table\u003e\u003c/div\u003e \u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003cp\u003eClinical Dementia Rating (CDR) values did not change in the placebo group, but those in the BRB group had an average CDR of 0 at the end of the 8-week intervention (Fig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003eA). It should be noted that neither amyloid beta nor p-tau was detectable in plasma from this patient population using an ELISA-based assay (data not shown). We then determined the effects of BRBs on Aβ-induced neurotoxicity in cultured neurons. Aβ42 oligomer treatment led to neurotoxicity in HT22 neuron cells, and BRB ethanol extract protected against Aβ-induced\u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003cp\u003edamage (Fig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003eB). It is possible that ethanol extract of BRBs contains anthocyanins that have been shown to cross the blood-brain barrier to protect the brain from Aβ toxicity (\u003cspan citationid=\"CR35\" class=\"CitationRef\"\u003e35\u003c/span\u003e).\u003c/p\u003e \u003cp\u003eBRBs decreased \u003cem\u003eProteobacteria\u003c/em\u003e and \u003cem\u003eFirmicutes\u003c/em\u003e to \u003cem\u003eBacteroidetes\u003c/em\u003e ratio in the feces (Fig.\u0026nbsp;\u003cspan refid=\"Fig2\" class=\"InternalRef\"\u003e2\u003c/span\u003eA).\u003c/p\u003e \u003cp\u003eFurther, BRBs decreased fecal \u003cem\u003eHelicobacter\u003c/em\u003e bacteria abundance (Fig.\u0026nbsp;\u003cspan refid=\"Fig2\" class=\"InternalRef\"\u003e2\u003c/span\u003eB), but increased fecal probiotics such as \u003cem\u003eLactobacillus reuteri\u003c/em\u003e, \u003cem\u003eBifidobacterium longum\u003c/em\u003e (Fig.\u0026nbsp;\u003cspan refid=\"Fig2\" class=\"InternalRef\"\u003e2\u003c/span\u003eC). Most interestingly, \u003cem\u003eAkkermansia muciniphila\u003c/em\u003e abundance increased in all subjects who consumed BRBs (Fig.\u0026nbsp;\u003cspan refid=\"Fig2\" class=\"InternalRef\"\u003e2\u003c/span\u003eD).\u003c/p\u003e \u003cp\u003e \u003csup\u003e13\u003c/sup\u003eC UBT was significantly lower at week 8 in the BRB group when compared to baseline (Table\u0026nbsp;\u003cspan refid=\"Tab2\" class=\"InternalRef\"\u003e2\u003c/span\u003e). However, this difference was resolved in week 10. Inflammatory markers, reflected by tumor necrosis factor α (TNF-α), interleukin-1β (IL-1β), interleukin-8 (IL-8), cyclooxygenase-2 (COX-2), and inducible nitric oxide synthase (iNOS) were measured at weeks 0, 4, and 8. At week 4, levels of TNF-α, IL-8, COX-2, and iNOS were significantly lower than at baseline, whereas levels of IL-1β were significantly higher. At week 8, levels of TNF-α, IL-8, and COX-2 were significantly lower than baseline, with IL-1β continuing to be significantly higher than levels at both baseline and week 4. The oxidative index was quantified by superoxide dismutase (SOD), catalase (CAT), thiobarbituric acid reactive substances (TBARS), and Trolox Equivalent Antioxidant Capacity (TEAC). At weeks 8 and 10, SOD, CAT, and TEAC levels were significantly higher than at baseline, but TBARS levels were significantly lower than at baseline.\u003c/p\u003e \u003cp\u003e \u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab2\" border=\"1\"\u003e \u003ccaption language=\"En\"\u003e \u003cdiv class=\"CaptionNumber\"\u003eTable 2\u003c/div\u003e \u003cdiv class=\"CaptionContent\"\u003e \u003cp\u003eBRB consumption decreased UBT and inflammatory markers, and oxidative indexes\u003c/p\u003e \u003c/div\u003e \u003c/caption\u003e \u003ccolgroup cols=\"8\"\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c1\" colnum=\"1\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c2\" colnum=\"2\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c3\" colnum=\"3\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c4\" colnum=\"4\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c5\" colnum=\"5\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c6\" colnum=\"6\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c7\" colnum=\"7\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c8\" colnum=\"8\"\u003e\u003c/div\u003e \u003cthead\u003e \u003ctr\u003e \u003cth align=\"left\" colspan=\"2\" nameend=\"c2\" namest=\"c1\"\u003e\u0026nbsp;\u003c/th\u003e \u003cth align=\"left\" colspan=\"2\" nameend=\"c4\" namest=\"c3\"\u003e \u003cp\u003eWeek 0\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colspan=\"2\" nameend=\"c6\" namest=\"c5\"\u003e \u003cp\u003eWeek 8\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c7\"\u003e \u003cp\u003eFollow up\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colspan=\"1\" nameend=\"c8\" namest=\"c8\"\u003e\u0026nbsp;\u003c/th\u003e \u003c/tr\u003e \u003c/thead\u003e \u003ctbody\u003e \u003ctr\u003e \u003ctd align=\"left\" colspan=\"7\" nameend=\"c7\" namest=\"c1\"\u003e \u003cp\u003e\u003cb\u003eUBT\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c8\" namest=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c2\" namest=\"c1\"\u003e \u003cp\u003eBRBs\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c4\" namest=\"c3\"\u003e \u003cp\u003e22.12\u0026thinsp;\u0026plusmn;\u0026thinsp;4.14\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c6\" namest=\"c5\"\u003e \u003cp\u003e9.36\u0026thinsp;\u0026plusmn;\u0026thinsp;6.36*\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e16.82\u0026thinsp;\u0026plusmn;\u0026thinsp;10.46*\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c8\" namest=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c2\" namest=\"c1\"\u003e \u003cp\u003ePlacebo\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c4\" namest=\"c3\"\u003e \u003cp\u003e22.98\u0026thinsp;\u0026plusmn;\u0026thinsp;1.78\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c6\" namest=\"c5\"\u003e \u003cp\u003e22.99\u0026thinsp;\u0026plusmn;\u0026thinsp;2.065\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e22.88\u0026thinsp;\u0026plusmn;\u0026thinsp;3.07\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c8\" namest=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colspan=\"7\" nameend=\"c7\" namest=\"c1\"\u003e \u003cp\u003e\u003cb\u003eInflammatory\u003c/b\u003e\u003c/p\u003e \u003cp\u003e\u003cb\u003emarkers\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c8\" namest=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c2\" namest=\"c1\"\u003e \u003cp\u003e\u003cb\u003eTNF-α (pg/mL)\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c4\" namest=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c6\" namest=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c8\" namest=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c2\" namest=\"c1\"\u003e \u003cp\u003eBRBs\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c4\" namest=\"c3\"\u003e \u003cp\u003e19.76\u0026thinsp;\u0026plusmn;\u0026thinsp;4.65\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c6\" namest=\"c5\"\u003e \u003cp\u003e6.85\u0026thinsp;\u0026plusmn;\u0026thinsp;3.27*\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e7.97\u0026thinsp;\u0026plusmn;\u0026thinsp;2.17*\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c8\" namest=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c2\" namest=\"c1\"\u003e \u003cp\u003ePlacebo\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c4\" namest=\"c3\"\u003e \u003cp\u003e19.81\u0026thinsp;\u0026plusmn;\u0026thinsp;2.21\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c6\" namest=\"c5\"\u003e \u003cp\u003e19.59\u0026thinsp;\u0026plusmn;\u0026thinsp;2.31\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e19.41\u0026thinsp;\u0026plusmn;\u0026thinsp;2.39\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c8\" namest=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c2\" namest=\"c1\"\u003e \u003cp\u003e\u003cb\u003eIL-1β (pg/mL)\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c4\" namest=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c6\" namest=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c8\" namest=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c2\" namest=\"c1\"\u003e \u003cp\u003eBRBs\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c4\" namest=\"c3\"\u003e \u003cp\u003e0.16\u0026thinsp;\u0026plusmn;\u0026thinsp;0.07\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c6\" namest=\"c5\"\u003e \u003cp\u003e0.12\u0026thinsp;\u0026plusmn;\u0026thinsp;0.05*\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e0.18\u0026thinsp;\u0026plusmn;\u0026thinsp;0.05*\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c8\" namest=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c2\" namest=\"c1\"\u003e \u003cp\u003ePlacebo\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c4\" namest=\"c3\"\u003e \u003cp\u003e0.19\u0026thinsp;\u0026plusmn;\u0026thinsp;0.08\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c6\" namest=\"c5\"\u003e \u003cp\u003e0.19\u0026thinsp;\u0026plusmn;\u0026thinsp;0.05\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e0.18\u0026thinsp;\u0026plusmn;\u0026thinsp;0.05\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c8\" namest=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c2\" namest=\"c1\"\u003e \u003cp\u003e\u003cb\u003eIL-8 (pg/mL)\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c4\" namest=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c6\" namest=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c8\" namest=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c2\" namest=\"c1\"\u003e \u003cp\u003eBRBs\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c4\" namest=\"c3\"\u003e \u003cp\u003e7.61\u0026thinsp;\u0026plusmn;\u0026thinsp;5.10\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c6\" namest=\"c5\"\u003e \u003cp\u003e4.63\u0026thinsp;\u0026plusmn;\u0026thinsp;3.63*\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e5.94\u0026thinsp;\u0026plusmn;\u0026thinsp;3.09\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c8\" namest=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c2\" namest=\"c1\"\u003e \u003cp\u003ePlacebo\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c4\" namest=\"c3\"\u003e \u003cp\u003e7.67\u0026thinsp;\u0026plusmn;\u0026thinsp;4.25\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c6\" namest=\"c5\"\u003e \u003cp\u003e7.86\u0026thinsp;\u0026plusmn;\u0026thinsp;4.90\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e7.79\u0026thinsp;\u0026plusmn;\u0026thinsp;4.23\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c8\" namest=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c2\" namest=\"c1\"\u003e \u003cp\u003e\u003cb\u003eCOX-2 (ng/mL)\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c4\" namest=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c6\" namest=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c8\" namest=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c2\" namest=\"c1\"\u003e \u003cp\u003eBRBs\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c4\" namest=\"c3\"\u003e \u003cp\u003e1.74\u0026thinsp;\u0026plusmn;\u0026thinsp;0.71\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c6\" namest=\"c5\"\u003e \u003cp\u003e0.87\u0026thinsp;\u0026plusmn;\u0026thinsp;0.56*\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e0.88\u0026thinsp;\u0026plusmn;\u0026thinsp;0.50*\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c8\" namest=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c2\" namest=\"c1\"\u003e \u003cp\u003ePlacebo\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c4\" namest=\"c3\"\u003e \u003cp\u003e1.68\u0026thinsp;\u0026plusmn;\u0026thinsp;0.65\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c6\" namest=\"c5\"\u003e \u003cp\u003e1.64\u0026thinsp;\u0026plusmn;\u0026thinsp;0.72\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e1.69\u0026thinsp;\u0026plusmn;\u0026thinsp;0.62\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c8\" namest=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c2\" namest=\"c1\"\u003e \u003cp\u003e\u003cb\u003eiNOS (ng/mL)\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c4\" namest=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c6\" namest=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c8\" namest=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c2\" namest=\"c1\"\u003e \u003cp\u003eBRBs\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c4\" namest=\"c3\"\u003e \u003cp\u003e21.15\u0026thinsp;\u0026plusmn;\u0026thinsp;8.50\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c6\" namest=\"c5\"\u003e \u003cp\u003e20.27\u0026thinsp;\u0026plusmn;\u0026thinsp;10.28\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e22.37\u0026thinsp;\u0026plusmn;\u0026thinsp;11.95\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c8\" namest=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c2\" namest=\"c1\"\u003e \u003cp\u003ePlacebo\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c4\" namest=\"c3\"\u003e \u003cp\u003e21.73\u0026thinsp;\u0026plusmn;\u0026thinsp;7.44\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c6\" namest=\"c5\"\u003e \u003cp\u003e22.00\u0026thinsp;\u0026plusmn;\u0026thinsp;7.75\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e21.21\u0026thinsp;\u0026plusmn;\u0026thinsp;7.24\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c8\" namest=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eOxidative indexes\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c3\" namest=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c5\" namest=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colspan=\"3\" nameend=\"c8\" namest=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eSOD (U/mL)\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c3\" namest=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c5\" namest=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colspan=\"3\" nameend=\"c8\" namest=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eBRBs\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c3\" namest=\"c2\"\u003e \u003cp\u003e696.42\u0026thinsp;\u0026plusmn;\u0026thinsp;35.30\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c5\" namest=\"c4\"\u003e \u003cp\u003e784.86\u0026thinsp;\u0026plusmn;\u0026thinsp;46.13*\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"3\" nameend=\"c8\" namest=\"c6\"\u003e \u003cp\u003e743.84\u0026thinsp;\u0026plusmn;\u0026thinsp;55.59*\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003ePlacebo\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c3\" namest=\"c2\"\u003e \u003cp\u003e690.72\u0026thinsp;\u0026plusmn;\u0026thinsp;34.84\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c5\" namest=\"c4\"\u003e \u003cp\u003e695.44\u0026thinsp;\u0026plusmn;\u0026thinsp;39.65\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"3\" nameend=\"c8\" namest=\"c6\"\u003e \u003cp\u003e691.54\u0026thinsp;\u0026plusmn;\u0026thinsp;41.35\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eCAT (U/mL)\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c3\" namest=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c5\" namest=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colspan=\"3\" nameend=\"c8\" namest=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eBRBs\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c3\" namest=\"c2\"\u003e \u003cp\u003e346.11\u0026thinsp;\u0026plusmn;\u0026thinsp;14.60\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c5\" namest=\"c4\"\u003e \u003cp\u003e360.84\u0026thinsp;\u0026plusmn;\u0026thinsp;8.26*\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"3\" nameend=\"c8\" namest=\"c6\"\u003e \u003cp\u003e360.21\u0026thinsp;\u0026plusmn;\u0026thinsp;9.22*\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003ePlacebo\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c3\" namest=\"c2\"\u003e \u003cp\u003e352.58\u0026thinsp;\u0026plusmn;\u0026thinsp;14.16\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c5\" namest=\"c4\"\u003e \u003cp\u003e351.95\u0026thinsp;\u0026plusmn;\u0026thinsp;11.30\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"3\" nameend=\"c8\" namest=\"c6\"\u003e \u003cp\u003e351.14\u0026thinsp;\u0026plusmn;\u0026thinsp;9.03\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eTBARS (\u0026micro;mol/L)\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c3\" namest=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c5\" namest=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colspan=\"3\" nameend=\"c8\" namest=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eBRBs\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c3\" namest=\"c2\"\u003e \u003cp\u003e4.14\u0026thinsp;\u0026plusmn;\u0026thinsp;1.20\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c5\" namest=\"c4\"\u003e \u003cp\u003e1.20\u0026thinsp;\u0026plusmn;\u0026thinsp;0.35*\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"3\" nameend=\"c8\" namest=\"c6\"\u003e \u003cp\u003e1.97\u0026thinsp;\u0026plusmn;\u0026thinsp;0.62*\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003ePlacebo\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c3\" namest=\"c2\"\u003e \u003cp\u003e4.20\u0026thinsp;\u0026plusmn;\u0026thinsp;0.57\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c5\" namest=\"c4\"\u003e \u003cp\u003e4.25\u0026thinsp;\u0026plusmn;\u0026thinsp;0.74\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"3\" nameend=\"c8\" namest=\"c6\"\u003e \u003cp\u003e4.30\u0026thinsp;\u0026plusmn;\u0026thinsp;0.90\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eTEAC (\u0026micro;mol Trolox/L)\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c3\" namest=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c5\" namest=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colspan=\"3\" nameend=\"c8\" namest=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eBRBs\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c3\" namest=\"c2\"\u003e \u003cp\u003e1319.77\u0026thinsp;\u0026plusmn;\u0026thinsp;191.90\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c5\" namest=\"c4\"\u003e \u003cp\u003e1840.68\u0026thinsp;\u0026plusmn;\u0026thinsp;188.73*\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"3\" nameend=\"c8\" namest=\"c6\"\u003e \u003cp\u003e1740.09\u0026thinsp;\u0026plusmn;\u0026thinsp;155.99*\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003ePlacebo\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c3\" namest=\"c2\"\u003e \u003cp\u003e1250.90\u0026thinsp;\u0026plusmn;\u0026thinsp;185.14\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c5\" namest=\"c4\"\u003e \u003cp\u003e1232.00\u0026thinsp;\u0026plusmn;\u0026thinsp;199.59\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"3\" nameend=\"c8\" namest=\"c6\"\u003e \u003cp\u003e1238.40\u0026thinsp;\u0026plusmn;\u0026thinsp;237.70\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003c/tbody\u003e \u003c/colgroup\u003e \u003ctfoot\u003e \u003ctr\u003e\u003ctd colspan=\"8\"\u003eThe results are expressed as mean\u0026thinsp;\u0026plusmn;\u0026thinsp;SD.\u003c/td\u003e\u003c/tr\u003e \u003ctr\u003e\u003ctd colspan=\"8\"\u003e*Difference between different times and week 0 within the same group, P\u0026thinsp;\u0026lt;\u0026thinsp;0.05.\u003c/td\u003e\u003c/tr\u003e \u003c/tfoot\u003e \u003c/table\u003e\u003c/div\u003e \u003c/p\u003e \u003cp\u003eRegarding changes in BMI, at week 4, the BRB group had a significantly lower body weight and BMI (p\u0026thinsp;\u0026lt;\u0026thinsp;0.05) compared to their week 0 measurements (Table\u0026nbsp;\u003cspan refid=\"Tab3\" class=\"InternalRef\"\u003e3\u003c/span\u003e). Adenosine monophosphate-activated protein kinase (AMPK) and leptin did not significantly change from baseline across the course of the study, but adiponectin was significantly increased from baseline at both weeks 8 and follow-up (p\u0026thinsp;\u0026lt;\u0026thinsp;0.01) (Table\u0026nbsp;\u003cspan refid=\"Tab3\" class=\"InternalRef\"\u003e3\u003c/span\u003e).\u003c/p\u003e \u003cp\u003e \u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab3\" border=\"1\"\u003e \u003ccaption language=\"En\"\u003e \u003cdiv class=\"CaptionNumber\"\u003eTable 3\u003c/div\u003e \u003cdiv class=\"CaptionContent\"\u003e \u003cp\u003eBody weight, BMI, body fat, AMPK, adiponectin, and leptin levels\u003c/p\u003e \u003c/div\u003e \u003c/caption\u003e \u003ccolgroup cols=\"5\"\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c1\" colnum=\"1\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c2\" colnum=\"2\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c3\" colnum=\"3\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c4\" colnum=\"4\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c5\" colnum=\"5\"\u003e\u003c/div\u003e \u003cthead\u003e \u003ctr\u003e \u003cth align=\"left\" colname=\"c1\"\u003e\u0026nbsp;\u003c/th\u003e \u003cth align=\"left\" colname=\"c2\"\u003e \u003cp\u003eWeek 0\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c3\"\u003e \u003cp\u003eWeek 4\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c4\"\u003e \u003cp\u003eWeek 8\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c5\"\u003e \u003cp\u003eFollow up\u003c/p\u003e \u003c/th\u003e \u003c/tr\u003e \u003c/thead\u003e \u003ctbody\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eBody weight (kg)\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eBRBs\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e83.41\u0026thinsp;\u0026plusmn;\u0026thinsp;10.39\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e82.65\u0026thinsp;\u0026plusmn;\u0026thinsp;9.82*\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e82.90\u0026thinsp;\u0026plusmn;\u0026thinsp;10.37\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e83.15\u0026thinsp;\u0026plusmn;\u0026thinsp;10.09\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003ePlacebo\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e74.14\u0026thinsp;\u0026plusmn;\u0026thinsp;8.47\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e73.90\u0026thinsp;\u0026plusmn;\u0026thinsp;7.72\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e73.45\u0026thinsp;\u0026plusmn;\u0026thinsp;7.49\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e73.83\u0026thinsp;\u0026plusmn;\u0026thinsp;7.96\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eBody Fat (%)\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eBRBs\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e30.61\u0026thinsp;\u0026plusmn;\u0026thinsp;5.88\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e30.33\u0026thinsp;\u0026plusmn;\u0026thinsp;6.17\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e30.14\u0026thinsp;\u0026plusmn;\u0026thinsp;6.16\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e30.17\u0026thinsp;\u0026plusmn;\u0026thinsp;5.76\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003ePlacebo\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e32.34\u0026thinsp;\u0026plusmn;\u0026thinsp;5.70\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e31.92\u0026thinsp;\u0026plusmn;\u0026thinsp;6.53\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e32.59\u0026thinsp;\u0026plusmn;\u0026thinsp;5.72\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e32.70\u0026thinsp;\u0026plusmn;\u0026thinsp;5.87\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eBMI (kg/m\u003c/b\u003e\u003csup\u003e\u003cb\u003e2\u003c/b\u003e\u003c/sup\u003e\u003cb\u003e)\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eBRBs\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e29.47\u0026thinsp;\u0026plusmn;\u0026thinsp;1.92\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e29.21\u0026thinsp;\u0026plusmn;\u0026thinsp;1.97*\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e29.30\u0026thinsp;\u0026plusmn;\u0026thinsp;2.06\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e29.41\u0026thinsp;\u0026plusmn;\u0026thinsp;2.01\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003ePlacebo\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e28.46\u0026thinsp;\u0026plusmn;\u0026thinsp;0.92\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e28.38\u0026thinsp;\u0026plusmn;\u0026thinsp;0.99\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e28.23\u0026thinsp;\u0026plusmn;\u0026thinsp;1.12\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e28.35\u0026thinsp;\u0026plusmn;\u0026thinsp;1.06\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eAMPK (pg/dL)\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eBRBs\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e9142.50\u0026thinsp;\u0026plusmn;\u0026thinsp;6734.93\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e9408.57\u0026thinsp;\u0026plusmn;\u0026thinsp;5844.41\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e9694.09\u0026thinsp;\u0026plusmn;\u0026thinsp;7408.22\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e9641.23\u0026thinsp;\u0026plusmn;\u0026thinsp;6664.65\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eAdiponectin (\u0026micro;g/mL)\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eBRBs\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e459.33\u0026thinsp;\u0026plusmn;\u0026thinsp;318.14\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e651.27\u0026thinsp;\u0026plusmn;\u0026thinsp;546.30\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e2394.65\u0026thinsp;\u0026plusmn;\u0026thinsp;1418.26*\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e2134.89\u0026thinsp;\u0026plusmn;\u0026thinsp;1153.37*\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eLeptin (\u0026micro;g/mL)\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eBRBs\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e5055.98\u0026thinsp;\u0026plusmn;\u0026thinsp;2969.55\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e4845.42\u0026thinsp;\u0026plusmn;\u0026thinsp;2049.15\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e4704.60\u0026thinsp;\u0026plusmn;\u0026thinsp;2689.98\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e4866.47\u0026thinsp;\u0026plusmn;\u0026thinsp;3584.98\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003c/tbody\u003e \u003c/colgroup\u003e \u003ctfoot\u003e \u003ctr\u003e\u003ctd colspan=\"5\"\u003eThe results are expressed as mean\u0026thinsp;\u0026plusmn;\u0026thinsp;SD.\u003c/td\u003e\u003c/tr\u003e \u003ctr\u003e\u003ctd colspan=\"5\"\u003e*Difference between different times and week 0 within the same group, P\u0026thinsp;\u0026lt;\u0026thinsp;0.05.\u003c/td\u003e\u003c/tr\u003e \u003ctr\u003e\u003ctd colspan=\"5\"\u003eAMPK: adenosine monophosphate-activated protein kinase\u003c/td\u003e\u003c/tr\u003e \u003c/tfoot\u003e \u003c/table\u003e\u003c/div\u003e \u003c/p\u003e \u003cp\u003eFurther, neither the BRB nor placebo groups had significant changes in blood lipid profile from their respective baselines at these time points (\u003cb\u003eSupplemental Table\u0026nbsp;2\u003c/b\u003e). Insulin, Homeostatic Model Assessment for Insulin Resistance score (HOMA-IR, quantified as [FBG * insulin]/405), and hemoglobin A1c (HbA1C) did not significantly change from baseline in the BRB and placebo groups (\u003cb\u003eSupplemental Table\u0026nbsp;3\u003c/b\u003e). However, FBG was significantly higher compared to baseline at week 4 and week 8 in the BRB group (p\u0026thinsp;\u0026lt;\u0026thinsp;0.05, p\u0026thinsp;\u0026lt;\u0026thinsp;0.01, respectively). Blood chemistry of subjects, reflected by glutamate oxaloacetate transaminase (GOT), glutamate pyruvate transaminase (GPT), blood urea nitrogen (BUN), creatinine, uric acid (UA), and creatinine phosphokinase (CPK), were not significantly different in either group across time points (\u003cb\u003eSupplemental Table\u0026nbsp;3\u003c/b\u003e). Mineral content was reflected by sodium (Na), potassium (K), chloride (Cl), and calcium (Ca) levels. K levels were significantly higher at week 4 compared to baseline in the BRB group (p\u0026thinsp;\u0026lt;\u0026thinsp;0.01) (\u003cb\u003eSupplemental Table\u0026nbsp;4\u003c/b\u003e). Na was significantly lower at follow-up compared to baseline in the BRB group (p\u0026thinsp;\u0026lt;\u0026thinsp;0.05).\u003c/p\u003e \u003cp\u003eAt week 4, those in the BRB group had a significantly lower rump circumference (RC) and triceps skin fold (TSF) (p\u0026thinsp;\u0026lt;\u0026thinsp;0.05) compared to their week 0 measurements (\u003cb\u003eSupplemental Table\u0026nbsp;5\u003c/b\u003e). At week 8, those in the BRB group had a significantly lower body fat percentage, RC, and mid-arm circumference (MAMC) compared to their week 0 measurements (p\u0026thinsp;\u0026lt;\u0026thinsp;0.05). Aside from these differences, waist circumference (WC), RC, MAMC, and TSF were not significantly different within the two groups at various recording times. At week 4, DBP was significantly lower than the baseline in the BRB group (p\u0026thinsp;\u0026lt;\u0026thinsp;0.05). While this difference resolved, SBP became significantly lower from baseline in the BRB group at follow-up (p\u0026thinsp;\u0026lt;\u0026thinsp;0.05) (\u003cb\u003eSupplemental Table\u0026nbsp;6\u003c/b\u003e).\u003c/p\u003e \u003cp\u003e \u003cb\u003eBRB extracts rescued\u003c/b\u003e \u003cb\u003eH. Pylori\u003c/b\u003e\u003cb\u003e-induced damages in cultured AGS cells\u003c/b\u003e\u003c/p\u003e \u003cp\u003eAn MTT assay was performed on applying crude BRB extract to AGS cells and \u003cem\u003eH. pylori\u003c/em\u003e to assess for protective effects of BRBs against \u003cem\u003eH. pylori\u003c/em\u003e, with cell viability assessed at 24 hours (Fig.\u0026nbsp;\u003cspan refid=\"Fig3\" class=\"InternalRef\"\u003e3\u003c/span\u003eA). When \u003cem\u003eH. pylori\u003c/em\u003e were added with no BRB extract or amoxicillin, cell viability decreased at 24 hours. However, when increasing concentrations of crude BRB extract were added to \u003cem\u003eH. pylori\u003c/em\u003e and the AGS cells, cells were rescued. A similar effect was seen with the gelatin-treated crude extract. \u003cem\u003eH. pylori\u003c/em\u003e adhesion was measured with varying doses of crude and gelatin-treated crude extracts. Increasing doses of crude and gelatin-treated crude extract reduced \u003cem\u003eH. pylori\u003c/em\u003e adhesion (Fig.\u0026nbsp;\u003cspan refid=\"Fig3\" class=\"InternalRef\"\u003e3\u003c/span\u003eB).\u003c/p\u003e \u003cp\u003eAnalysis was performed on proteins associated specifically with \u003cem\u003eH. pylori\u003c/em\u003e. Western blot was performed to assess the expression of cytotoxin-associated protein A (CagA), associated with the induction of intestinal metaplasia and gastric adenocarcinoma\u003csup\u003e20\u003c/sup\u003e. CagA expression was significantly reduced by both crude and gelatin-treated crude extract (Fig.\u0026nbsp;\u003cspan refid=\"Fig3\" class=\"InternalRef\"\u003e3\u003c/span\u003eC). Western blotting was also utilized to determine the expression of vacuolating cytotoxin A (VacA), another \u003cem\u003eH. pylori\u003c/em\u003e product that modulates the function of immunologic cells and is associated with \u003cem\u003eH. pylori\u003c/em\u003e colonization, peptic ulcer disease, and gastric adenocarcinoma\u003csup\u003e21\u003c/sup\u003e. VacA expression was\u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003cp\u003esignificantly decreased by crude extract and crude extract treated with gelatin (Fig.\u0026nbsp;\u003cspan refid=\"Fig3\" class=\"InternalRef\"\u003e3\u003c/span\u003eC). Lastly, interleukin-8 (IL-8) expression has been shown to be induced by \u003cem\u003eH. pylori\u003c/em\u003e infection; the upregulation of IL-8 related to \u003cem\u003eH. pylori\u003c/em\u003e is associated with gastritis and possibly gastric malignancies\u003csup\u003e22,23\u003c/sup\u003e. When \u003cem\u003eH. pylori\u003c/em\u003e was added to the AGS cell culture, IL-8 expression was significantly increased (Fig.\u0026nbsp;\u003cspan refid=\"Fig3\" class=\"InternalRef\"\u003e3\u003c/span\u003eD). Both extracts significantly decreased \u003cem\u003eH. pylori\u003c/em\u003e-induced IL-8.\u003c/p\u003e \u003cp\u003eOverall, both crude extract and crude extract-treated with gelatin decreased \u003cem\u003eH. pylori\u003c/em\u003e-induced damages, including increasing cell viability, decreasing \u003cem\u003eH. pylori\u003c/em\u003e adhesion and expression of CagA, VacA, and IL-8 in cultured AGS cells (Fig.\u0026nbsp;\u003cspan refid=\"Fig3\" class=\"InternalRef\"\u003e3\u003c/span\u003eA-\u003cspan refid=\"Fig3\" class=\"InternalRef\"\u003e3\u003c/span\u003eD).\u003c/p\u003e \u003cdiv id=\"Sec9\" class=\"Section2\"\u003e \u003ch2\u003eBRB extracts promoted 3T3-L1 pre-adipocyte viability and decreased lipid accumulation in 3T3-L1c mature adipocytes\u003c/h2\u003e \u003cp\u003e3T3-L1 pre-adipocytes were incubated with crude extract, gelatin-treated crude extract, and tannin fraction. A significant increase in viability was seen in 3T3-L1 pre-adipocytes treated with all three extracts (Fig.\u0026nbsp;\u003cspan refid=\"Fig3\" class=\"InternalRef\"\u003e3\u003c/span\u003eE). Oil-red staining was then performed to assess the effects of those three extracts on lipid accumulation in 3T3-L1 mature adipocyte cells. All three BRB extracts significantly decreased lipid accumulation (Fig.\u0026nbsp;\u003cspan refid=\"Fig3\" class=\"InternalRef\"\u003e3\u003c/span\u003eF).\u003c/p\u003e \u003c/div\u003e"},{"header":"Discussions","content":"\u003cp\u003eThe purpose of this study was to assess whether BRBs had meaningful effects on markers of \u003cem\u003eH. pylori\u003c/em\u003e infection and obesity, thereby impacting AD dementia. We conducted a randomized, placebo-controlled clinical trial, which examined the effects of BRBs on obese subjects who were \u003cem\u003eH. pylori\u003c/em\u003e positive and had AD as measured by a CDR of 0.5. BRBs significantly improved cognitive function by moving CDR from 0.5 to zero and decreased UBT and BMI. These effects are associated with significant anti-inflammatory and antioxidant capacity.\u003c/p\u003e \u003cp\u003eAlthough neither amyloid beta nor p-tau was detectable in plasma from this AD patient population using an ELISA-based assay (data not shown), our results could suggest that they could be at an early stage of AD. More sensitive ultrasensitive platforms, including SIMOA, IMR, MSD, and Elecsys immunoassays, that overcomes the complex interferences of blood proteins, heterophilic antibodies, and low target biomarkers\u003csup\u003e24\u003c/sup\u003e, will be used to confirm the levels of blood amyloid beta and p-tau in this AD population in the future.\u003c/p\u003e \u003cp\u003eGut microbiota is a complex microorganism in the human GI tract that plays a crucial role in maintaining health\u003csup\u003e25\u003c/sup\u003e. Gut microbiota can help to metabolize some indigestible dietary components and to prevent pathogen colonization in the GI tract\u003csup\u003e26\u003c/sup\u003e. Gut microbiota mainly comprises two major phyla, \u003cem\u003eFirmicutes\u003c/em\u003e and \u003cem\u003eBacteroidetes\u003c/em\u003e, and some minor phyla, such as \u003cem\u003eProteobacteria\u003c/em\u003e, and \u003cem\u003eActinobacteria\u003c/em\u003e\u003csup\u003e27\u003c/sup\u003e. Alteration of gut microbiota can influence different metabolic disorders, the immune system, and also the central nervous system through the gut-brain axis\u003csup\u003e28\u003c/sup\u003e. Recent studies show that there are links between gut microbiota and Alzheimer\u0026rsquo;s disease. Gut microbiota is affected by lifestyle, including food intake and habits. Host dietary components are used as substrates and energy sources to prevent pathogenic bacteria and produce beneficial metabolites\u003csup\u003e29\u003c/sup\u003e. \u003cem\u003eProteobacteria\u003c/em\u003e is one of the gut microbiota phyla that comprises several human pathogens\u003csup\u003e30\u003c/sup\u003e. Pathogenic infections such as \u003cem\u003eChlamydophila pneumoniae, Helicobacter pylori, Toxoplasma gondii\u003c/em\u003e, and others might contribute to the pathogenesis of Alzheimer\u0026rsquo;s disease\u003csup\u003e31\u003c/sup\u003e. Besides \u003cem\u003eProteobacteria\u003c/em\u003e, gut dysbiosis is linked to AD progression. Gut dysbiosis is a phenomenon where gut microbiota is altered that mainly showed by increasing ratio of \u003cem\u003eFirmicutes\u003c/em\u003e to \u003cem\u003eBacteroidetes\u003c/em\u003e\u003csup\u003e32,33\u003c/sup\u003e. Gut dysbiosis is associated with several AD pathology, such as accumulation of intestinal amyloid precursor protein (APP), induction of systemic inflammation by proinflammatory neurotoxin and bacterial lipopolysaccharide (LPS), and alteration of blood-brain barrier (BBB)\u003csup\u003e33,34,35,36\u003c/sup\u003e.\u003c/p\u003e \u003cp\u003eBRBs contain high amounts of polyphenols which can act as antimicrobial agent, especially for \u003cem\u003eH. pylori\u003c/em\u003e\u003csup\u003e37,38\u003c/sup\u003e. \u003cem\u003eHelicobacter\u003c/em\u003e, particularly \u003cem\u003eHelicobacter pylori\u003c/em\u003e is a gram-negative bacterium that mainly resides in the gastric and induces several inflammatory responses due to its virulence factor\u003csup\u003e39\u003c/sup\u003e. \u003cem\u003eH. pylori\u003c/em\u003e infection can cause disruption of tight junction, and this disruption can lead to increased proinflammatory cytokines and harmful metabolites (e.g. bacterial amyloids and trimethylamine-N-oxide (TMAO)) \u003csup\u003e40\u003c/sup\u003e. These harmful substances produced by pathogens enter the circulatory system, disrupt BBB and induce an immune response in the central nervous system\u003csup\u003e33\u003c/sup\u003e. \u003cem\u003eH. pylori\u003c/em\u003e can induce a neuroinflammatory response in the C57BL6 WT mice through circulating proinflammatory cytokines\u003csup\u003e41\u003c/sup\u003e. Eradication of \u003cem\u003eH. pylori\u003c/em\u003e from AD subjects result in improved cognition compared with AD patients who did not receive \u003cem\u003eH. pylori\u003c/em\u003e eradication therapy\u003csup\u003e42\u003c/sup\u003e.\u003c/p\u003e \u003cp\u003eOn the other hand, BRB intervention also increased probiotics such as \u003cem\u003eLactobacillus\u003c/em\u003e and \u003cem\u003eBifidobacterium.\u003c/em\u003e Probiotics play an essential role in maintaining gut health due to their ability to metabolize undigested food components and produce metabolites such as gamma-aminobutyric acid (GABA) and short-chain fatty acids (SCFA)\u003csup\u003e43\u003c/sup\u003e. GABA is an inhibitory neurotransmitter that reduces stress and anxiety\u003csup\u003e44\u003c/sup\u003e. In Alzheimer\u0026rsquo;s patients, GABA concentration is significantly decreased and causes cognitive impairment\u003csup\u003e45\u003c/sup\u003e. SCFA are the metabolites from dietary fiber fermentation derived from gut microbiota and linked to gut-brain interaction\u003csup\u003e46\u003c/sup\u003e. SCFA can cross the BBB and repair neuronal by upregulating cyclic-AMP response element binding protein (CREB) and brain-derived neurotrophic factor (BDNF), inhibiting inflammatory response in the central nervous system, reducing Aβ aggregation into neurotoxic oligomer, reducing tau protein hyperphosphorylation and reducing the cognitive impairment in AD subjects\u003csup\u003e46,47\u003c/sup\u003e. Our study result show that BRB supplementation increase \u003cem\u003eBacteriodetes\u003c/em\u003e and probiotic concentration. This result might indirectly link to increase production of GABA and SCFA due to \u003cem\u003eBacteriodetes\u003c/em\u003e such as \u003cem\u003eBacteriodes and Parabacteroides, and Bifidobacterium\u003c/em\u003e ability to produce GABA\u003csup\u003e48, 49\u003c/sup\u003e and lactic acid bacteria (\u003cem\u003eLactobacillus\u003c/em\u003e and \u003cem\u003eBifidobacterium\u003c/em\u003e) to produces SCFA\u003csup\u003e50\u003c/sup\u003e but further study is needed to support this statement.\u003c/p\u003e \u003cp\u003e \u003cem\u003eAkkermansia muciniphilla\u003c/em\u003e is a gram-negative bacterium belonging to \u003cem\u003eVerrucomicrobiota\u003c/em\u003e, constitutting 1\u0026ndash;4% of the total fecal microbiome\u003csup\u003e51,52\u003c/sup\u003e. \u003cem\u003eAkkermansia muciniphilla\u003c/em\u003e can degrade intestinal mucin and produce acetate and propionate as substrates for other gut microbiome and the host\u003csup\u003e53\u003c/sup\u003e. \u003cem\u003eAkkermansia muciniphilla\u003c/em\u003e abundance is decreased in obesity, inflammation, and diabetes in the human GI tract \u003csup\u003e54\u003c/sup\u003e. BRBs are rich in polyphenols, and several studies have shown that polyphenols promote the growth of \u003cem\u003eAkkermansia muciniphilla\u003c/em\u003e in the mice GI tract\u003csup\u003e55\u0026ndash;57\u003c/sup\u003e. Interestingly, we showed that BRBs increased the abundance of \u003cem\u003eAkkermansia muciniphila\u003c/em\u003e, a bacterium associated with reduced inflammation, and decreased in patients with mild cognitive decline\u003csup\u003e58\u003c/sup\u003e, that could delay the cognitive decline and improved CDR in patients with Alzheimer's disease.\u003c/p\u003e \u003cp\u003eUBT values and inflammatory markers provided indices of efficacy against \u003cem\u003eH. pylori\u003c/em\u003e infection. Overall, UBT values were meaningfully improved by BRB intervention, but this effect did not persist when BRB supplementation was discontinued. While most of the inflammatory markers, excluding iNOS, did indicate less inflammatory profiles with continued BRB supplementation, the post-intervention impacts were not explored, so additional study is needed to assess whether the alterations in inflammatory profile continue to benefit even after BRB treatment. These results indicate that BRBs may exert some degree of defense against \u003cem\u003eH. pylori\u003c/em\u003e infection, but the results only support these benefits so long as BRBs continue to be consumed in the diet.\u003c/p\u003e \u003cp\u003eAssays were performed first on AGS and 3T3-L1 pre-adipocyte cell models to explore whether BRBs might have tangible results in human patients. While BRBs significantly improved the viability rates of AGS cells exposed to \u003cem\u003eH. pylori\u003c/em\u003e. Further, both crude and gelatin-treated crude extracts reduced the adhesion rates of \u003cem\u003eH. pylori\u003c/em\u003e in the AGS cell cultures. However, here it is important to note that the amoxicillin control also showed the same level of a significant reduction in adhesion rates as BRBs, suggesting that BRBs were similarly, but not more or less effective, than amoxicillin alone in reducing adhesion rates of \u003cem\u003eH. pylori\u003c/em\u003e. Both crude extract and crude extract treated with gelatin decreased CagA and VacA protein expressions. These results suggest that while BRB extract can provide statistically comparable effects when compared to amoxicillin in reducing the expression of these \u003cem\u003eH. pylori\u003c/em\u003e genes, it must be administered at sufficiently high doses. However, considering that amoxicillin is currently part of status quo treatment for \u003cem\u003eH. pylori\u003c/em\u003e based on extensive research demonstrating its effectiveness, further research is needed to determine whether BRBs are a reasonable alternative to amoxicillin, seeing as they do appear to provide a significant additional benefit against \u003cem\u003eH. pylori\u003c/em\u003e infection in AGS cells. Another route of exploration may involve seeing if the effects of amoxicillin and BRBs are cumulative; that is, whether the supplementation with BRBs of a pre-established amoxicillin regimen to treat \u003cem\u003eH. pylori\u003c/em\u003e might be more effective than amoxicillin alone.\u003c/p\u003e \u003cp\u003eThe 3T3-L1 pre-adipocyte and mature adipocyte models, crude extract, gelatin-treated crude extract, and tannins fraction were all effective. This result supports the notion that crude BRB extract is sufficient to show the effects. Tannins in the extract are essential. Gelatin-treated crude extract or tannins fraction and that more components than just tannins are likely active in reducing lipid accumulation. It is expected that the effects of crude BRB extract cannot be attributed to tannins alone. Still, more research will be needed to determine which additional components confer the other advantage to crude BRB extract.\u003c/p\u003e \u003cp\u003eGiven the activity of BRBs against \u003cem\u003eH. pylori\u003c/em\u003e, as demonstrated by the AGS cells, and against obesity, as shown by the 3T3-L1 pre-adipocyte cells, it was anticipated that they might exert similar effects on actual patients. Although BRBs did affect physiologic markers of obesity, including body weight, BMI, body fat, RC, MAMC, and TSF, these effects did not persist into the follow-up stage. Interestingly, while body fat, RC, and MAMC did a downtrend throughout the intervention, reaching significance by week 8, the other markers did not show trends with continued intervention. This finding suggests that adding BRBs to the diet provided variable benefits, with some lasting only temporarily despite additional BRB consumption and others taking some time to manifest. Overall, all benefits were lost within 2 weeks after the intervention was concluded, so continued consumption of BRBs appears to be necessary. BRBs did not confer any significant disadvantage as assessed by the obesity markers.\u003c/p\u003e \u003cp\u003eInterestingly, SBP only showed a significant reduction at follow-up, 2 weeks post-intervention, while DBP was only reduced at week 4. BRBs did not exert meaningful effects on blood lipid profiles. They did not affect markers of diabetes other than fasting blood glucose, which was significantly increased with an upward trend throughout the intervention. This trend merits further exploration as increased FBG is not a desirable result; while the average levels within subjects were maintained below pre-diabetes levels, it is uncertain whether continued consumption of BRBs would have breached that threshold. One of the most significant changes related to obesity was seen in adiponectin levels, which substantially increased after both 8 weeks of treatment and 2 weeks post-intervention. Low adiponectin levels are associated with obesity, diabetes, hyperlipidemia, and other conditions that place patients at high risk for cardiovascular disease, while high adiponectin levels are associated with a healthier metabolic profile, so it appears that BRBs resulted in a meaningful benefit here\u003csup\u003e59,60\u003c/sup\u003e.\u003c/p\u003e \u003cp\u003eIn conclusion, our results provide the first evidence that BRBs enhanced fecal \u003cem\u003eAkkermansia muciniphila\u003c/em\u003e abundance and protectively altered parameters of \u003cem\u003eH. pylori\u003c/em\u003e infection and obesity, leading to dampened inflammation and oxidation, which could result in improved cognitive functions in AD patients. Longer and larger randomized clinical trials of BRB interventions targeting \u003cem\u003eH. pylori\u003c/em\u003e infection, obesity, or AD are warranted to confirm the results from this pilot trial.\u003c/p\u003e "},{"header":"Declarations","content":"\u003cp\u003e\u003cstrong\u003eConsent Statement:\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe authors confirmed that all human subjectslprovided informed consent.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eAcknowledgments\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThis work was supported by NIH grants CA148818 and USDA/NIFA 2020-67017-30843 (to L.-S. Wang)\u0026nbsp;, and also supported by National Science and Technology Council of Taiwan grants 111-2320-B-040-003-MY3 (to C.-K Wang).\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eConflicts of Interest\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eAll authors declare the absence of any competing interests.\u003c/p\u003e"},{"header":"References","content":"\u003col\u003e\u003cli\u003e\u003cspan\u003eGlobal, regional, and national burden of Alzheimer's disease and other dementias, 1990\u0026ndash;2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. Jan 2019;18(1):88\u0026ndash;106. doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/s1474-4422(18)30403-4\u003c/span\u003e\u003cspan address=\"10.1016/s1474-4422(18)30403-4\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eScheltens P, De Strooper B, Kivipelto M, et al. Alzheimer's disease. \u003cem\u003eLancet\u003c/em\u003e. Apr 24 2021;397(10284):1577\u0026ndash;1590. doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/s0140-6736(20)32205-4\u003c/span\u003e\u003cspan address=\"10.1016/s0140-6736(20)32205-4\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eBrown LM. Helicobacter pylori: epidemiology and routes of transmission. Epidemiol Rev. 2000;22(2):283\u0026ndash;97. doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1093/oxfordjournals.epirev.a018040\u003c/span\u003e\u003cspan address=\"10.1093/oxfordjournals.epirev.a018040\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eKhoder G, Muhammad JS, Mahmoud I, Soliman SSM, Burucoa C. Prevalence of Helicobacter pylori and Its Associated Factors among Healthy Asymptomatic Residents in the United Arab Emirates. Pathogens. Apr 1 2019;8(2)doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.3390/pathogens8020044\u003c/span\u003e\u003cspan address=\"10.3390/pathogens8020044\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eLee YC, Dore MP, Graham DY. Diagnosis and Treatment of Helicobacter pylori Infection. Annu Rev Med. Jan 27 2022;73:183\u0026ndash;195. doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1146/annurev-med-042220-020814\u003c/span\u003e\u003cspan address=\"10.1146/annurev-med-042220-020814\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eDuck WM, Sobel J, Pruckler JM, et al. Antimicrobial resistance incidence and risk factors among Helicobacter pylori-infected persons, United States. Emerg Infect Dis. Jun 2004;10(6):1088\u0026ndash;94. doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.3201/eid1006.030744\u003c/span\u003e\u003cspan address=\"10.3201/eid1006.030744\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eLiu L, Huh JR, Shah K. Microbiota and the gut-brain-axis: Implications for new therapeutic design in the CNS. EBioMedicine. Mar 2022;77:103908. doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/j.ebiom.2022.103908\u003c/span\u003e\u003cspan address=\"10.1016/j.ebiom.2022.103908\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eBaj J, Forma A, Flieger W, et al. Helicobacter pylori Infection and Extragastric Diseases-A Focus on the Central Nervous System. Cells. Aug 25 2021;10(9)doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.3390/cells10092191\u003c/span\u003e\u003cspan address=\"10.3390/cells10092191\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003ePellicano R, Ianiro G, Fagoonee S, Settanni CR, Gasbarrini A. Review: Extragastric diseases and Helicobacter pylori. Helicobacter. Sep 2020;25 Suppl 1:e12741. doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1111/hel.12741\u003c/span\u003e\u003cspan address=\"10.1111/hel.12741\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eHeneka MT, Carson MJ, El Khoury J, et al. Neuroinflammation in Alzheimer's disease. Lancet Neurol. Apr 2015;14(4):388\u0026ndash;405. doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/s1474-4422(15)70016-5\u003c/span\u003e\u003cspan address=\"10.1016/s1474-4422(15)70016-5\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eQiu C, Kivipelto M, von Strauss E. Epidemiology of Alzheimer's disease: occurrence, determinants, and strategies toward intervention. Dialogues Clin Neurosci. 2009;11(2):111\u0026ndash;28. doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.31887/DCNS.2009.11.2/cqiu\u003c/span\u003e\u003cspan address=\"10.31887/DCNS.2009.11.2/cqiu\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eSilva MVF, Loures CMG, Alves LCV, de Souza LC, Borges KBG, Carvalho MDG. Alzheimer's disease: risk factors and potentially protective measures. J Biomed Sci. May 9 2019;26(1):33. doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1186/s12929-019-0524-y\u003c/span\u003e\u003cspan address=\"10.1186/s12929-019-0524-y\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eZaidi SF, Ahmed K, Saeed SA, Khan U, Sugiyama T. Can Diet Modulate Helicobacter pylori-associated Gastric Pathogenesis? An Evidence-Based Analysis. Nutr Cancer. Oct 2017;69(7):979\u0026ndash;989. doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1080/01635581.2017.1359310\u003c/span\u003e\u003cspan address=\"10.1080/01635581.2017.1359310\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eWang LS, Echeveste CE, Yu J, et al. Can Natural Products Suppress Resistant Helicobacter pylori to Fight Against Gastric Diseases in Humans? \u003cem\u003eeFood\u003c/em\u003e. Feb 2020;1(1):53\u0026ndash;60. doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.2991/efood.k.200211.001\u003c/span\u003e\u003cspan address=\"10.2991/efood.k.200211.001\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eHuang YW, Echeveste CE, Oshima K, et al. Anti-colonic Inflammation by Black Raspberries through Regulating Toll-like Receptor-4 Signaling in Interlukin-10 Knockout Mice. J Cancer Prev. Jun 30 2020;25(2):119\u0026ndash;125. doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.15430/jcp.2020.25.2.119\u003c/span\u003e\u003cspan address=\"10.15430/jcp.2020.25.2.119\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMontrose DC, Horelik NA, Madigan JP, et al. Anti-inflammatory effects of freeze-dried black raspberry powder in ulcerative colitis. Carcinogenesis. Mar 2011;32(3):343\u0026ndash;50. doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1093/carcin/bgq248\u003c/span\u003e\u003cspan address=\"10.1093/carcin/bgq248\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eWang LS, Kuo CT, Stoner K, et al. Dietary black raspberries modulate DNA methylation in dextran sodium sulfate (DSS)-induced ulcerative colitis. Carcinogenesis. Dec 2013;34(12):2842\u0026ndash;50. doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1093/carcin/bgt310\u003c/span\u003e\u003cspan address=\"10.1093/carcin/bgt310\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eWang LS, Hecht SS, Carmella SG, et al. Anthocyanins in black raspberries prevent esophageal tumors in rats. Cancer Prev Res (Phila). Jan 2009;2(1):84\u0026ndash;93. doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1158/1940-6207.Capr-08-0155\u003c/span\u003e\u003cspan address=\"10.1158/1940-6207.Capr-08-0155\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003ePan P, Kang S, Wang Y, et al. Black Raspberries Enhance Natural Killer Cell Infiltration into the Colon and Suppress the Progression of Colorectal Cancer. Front Immunol. 2017;8:997. doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.3389/fimmu.2017.00997\u003c/span\u003e\u003cspan address=\"10.3389/fimmu.2017.00997\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMurata-Kamiya N, Kurashima Y, Teishikata Y, et al. Helicobacter pylori CagA interacts with E-cadherin and deregulates the beta-catenin signal that promotes intestinal transdifferentiation in gastric epithelial cells. \u003cem\u003eOncogene\u003c/em\u003e. Jul 12 2007;26(32):4617-26. doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1038/sj.onc.1210251\u003c/span\u003e\u003cspan address=\"10.1038/sj.onc.1210251\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eCover TL, Blanke SR. Helicobacter pylori VacA, a paradigm for toxin multifunctionality. Nat Rev Microbiol. Apr 2005;3(4):320\u0026ndash;32. doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1038/nrmicro1095\u003c/span\u003e\u003cspan address=\"10.1038/nrmicro1095\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eEftang LL, Esbensen Y, Tann\u0026aelig;s TM, Bukholm IR, Bukholm G. Interleukin-8 is the single most up-regulated gene in whole genome profiling of H. pylori exposed gastric epithelial cells. BMC Microbiol. Jan 17 2012;12:9. doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1186/1471-2180-12-9\u003c/span\u003e\u003cspan address=\"10.1186/1471-2180-12-9\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eCrabtree JE, Peichl P, Wyatt JI, Stachl U, Lindley IJ. Gastric interleukin-8 and IgA IL-8 autoantibodies in Helicobacter pylori infection. Scand J Immunol. Jan 1993;37(1):65\u0026ndash;70. doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1111/j.1365-3083.1993.tb01666.x\u003c/span\u003e\u003cspan address=\"10.1111/j.1365-3083.1993.tb01666.x\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eQu Y, Ma YH, Huang YY, et al. Blood biomarkers for the diagnosis of amnestic mild cognitive impairment and Alzheimer's disease: A systematic review and meta-analysis. Neurosci Biobehav Rev. Sep 2021;128:479\u0026ndash;486. doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/j.neubiorev.2021.07.007\u003c/span\u003e\u003cspan address=\"10.1016/j.neubiorev.2021.07.007\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eJandhyala SM, Talukdar R, Subramanyam C, Vuyyuru H, Sasikala M, Nageshwar Reddy D. Role of the normal gut microbiota. World J Gastroenterol. 2015;21(29):8787\u0026ndash;8803. doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.3748/wjg.v21.i29.8787\u003c/span\u003e\u003cspan address=\"10.3748/wjg.v21.i29.8787\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMagne F, Gotteland M, Gauthier L, et al. The Firmicutes/Bacteroidetes Ratio: A Relevant Marker of Gut Dysbiosis in Obese Patients?. \u003cem\u003eNutrients\u003c/em\u003e. 2020;12(5):1474. Published 2020 May 19. doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.3390/nu12051474\u003c/span\u003e\u003cspan address=\"10.3390/nu12051474\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eQin J, Li R, Raes J, et al. A human gut microbial gene catalogue established by metagenomic sequencing. Nature. 2010;464(7285):59\u0026ndash;65. doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1038/nature08821\u003c/span\u003e\u003cspan address=\"10.1038/nature08821\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eStrandwitz P. Neurotransmitter modulation by the gut microbiota. Brain Res. 2018;1693(Pt B):128\u0026ndash;133. doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/j.brainres.2018.03.015\u003c/span\u003e\u003cspan address=\"10.1016/j.brainres.2018.03.015\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eKesika P, Suganthy N, Sivamaruthi BS, Chaiyasut C. Role of gut-brain axis, gut microbial composition, and probiotic intervention in Alzheimer's disease. Life Sci. 2021;264:118627. doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/j.lfs.2020.118627\u003c/span\u003e\u003cspan address=\"10.1016/j.lfs.2020.118627\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eRizzatti G, Lopetuso LR, Gibiino G, Binda C, Gasbarrini A. Proteobacteria: A Common Factor in Human Diseases. Biomed Res Int. 2017;2017:9351507. doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1155/2017/9351507\u003c/span\u003e\u003cspan address=\"10.1155/2017/9351507\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eHu X, Wang T, Jin F. Alzheimer's disease and gut microbiota. Sci China Life Sci. 2016;59(10):1006\u0026ndash;1023. doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1007/s11427-016-5083-9\u003c/span\u003e\u003cspan address=\"10.1007/s11427-016-5083-9\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eBeliz\u0026aacute;rio JE, Faintuch J. Microbiome and Gut Dysbiosis. Exp Suppl. 2018;109:459\u0026ndash;476. doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1007/978-3-319-74932-7_13\u003c/span\u003e\u003cspan address=\"10.1007/978-3-319-74932-7_13\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eLiu S, Gao J, Zhu M, Liu K, Zhang HL. Gut Microbiota and Dysbiosis in Alzheimer's Disease: Implications for Pathogenesis and Treatment. Mol Neurobiol. 2020;57(12):5026\u0026ndash;5043. doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1007/s12035-020-02073-3\u003c/span\u003e\u003cspan address=\"10.1007/s12035-020-02073-3\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eBrandscheid C, Schuck F, Reinhardt S, et al. Altered Gut Microbiome Composition and Tryptic Activity of the 5xFAD Alzheimer's Mouse Model. J Alzheimers Dis. 2017;56(2):775\u0026ndash;788. doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.3233/JAD-160926\u003c/span\u003e\u003cspan address=\"10.3233/JAD-160926\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eCryan JF, O'Riordan KJ, Cowan CSM, et al. The Microbiota-Gut-Brain Axis. Physiol Rev. 2019;99(4):1877\u0026ndash;2013. doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1152/physrev.00018.2018\u003c/span\u003e\u003cspan address=\"10.1152/physrev.00018.2018\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eHolmes C, Cunningham C, Zotova E, Culliford D, Perry VH. Proinflammatory cytokines, sickness behavior, and Alzheimer disease. Neurology. 2011;77(3):212\u0026ndash;218. doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1212/WNL.0b013e318225ae07\u003c/span\u003e\u003cspan address=\"10.1212/WNL.0b013e318225ae07\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eGoodman C, Lyon KN, Scotto A, et al. A High-Throughput Metabolic Microarray Assay Reveals Antibacterial Effects of Black and Red Raspberries and Blackberries against \u003cem\u003eHelicobacter pylori\u003c/em\u003e Infection. \u003cem\u003eAntibiotics (Basel)\u003c/em\u003e. 2021;10(7):845. Published 2021 Jul 12. doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.3390/antibiotics10070845\u003c/span\u003e\u003cspan address=\"10.3390/antibiotics10070845\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eYu, Ji \u0026amp; Yu, Na-Jeong \u0026amp; Gim, Sung \u0026amp; Lee, Sujin \u0026amp; Kwon, Gyoo \u0026amp; Yuk, Hyun-Gyun. (2019). Antimicrobial effect of black raspberry (Rubus occidentalis, Bokbunja) extract against Escherichia coli and Staphylococcus aureus. Korean J. Food Preserv.. 26. 360\u0026ndash;364. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.11002/kjfp.2019.26.3.360\u003c/span\u003e\u003cspan address=\"10.11002/kjfp.2019.26.3.360\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eGuerra-Valle M, Orellana-Palma P, Petzold G. Plant-Based Polyphenols: Anti-\u003cem\u003eHelicobacter pylori\u003c/em\u003e Effect and Improvement of Gut Microbiota. \u003cem\u003eAntioxidants (Basel)\u003c/em\u003e. 2022;11(1):109. Published 2022 Jan 4. doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.3390/antiox11010109\u003c/span\u003e\u003cspan address=\"10.3390/antiox11010109\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eWu D, Cao M, Peng J, et al. The effect of trimethylamine N-oxide on Helicobacter pylori-induced changes of immunoinflammatory genes expression in gastric epithelial cells. Int Immunopharmacol. 2017;43:172\u0026ndash;178. doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/j.intimp.2016.11.032\u003c/span\u003e\u003cspan address=\"10.1016/j.intimp.2016.11.032\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eAlbaret G, Sifr\u0026eacute; E, Floch P, et al. Alzheimer's Disease and Helicobacter pylori Infection: Inflammation from Stomach to Brain?. J Alzheimers Dis. 2020;73(2):801\u0026ndash;809. doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.3233/JAD-190496\u003c/span\u003e\u003cspan address=\"10.3233/JAD-190496\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eKountouras J. Helicobacter pylori: an intruder involved in conspiring glaucomatous neuropathy. Br J Ophthalmol. 2009;93(11):1413\u0026ndash;1415. doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1136/bjo.2009.159046\u003c/span\u003e\u003cspan address=\"10.1136/bjo.2009.159046\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eGupta V, Garg R. Probiotics. Indian J Med Microbiol. 2009;27(3):202\u0026ndash;209. doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.4103/0255-0857.53201\u003c/span\u003e\u003cspan address=\"10.4103/0255-0857.53201\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eBarrett E, Ross RP, O'Toole PW, Fitzgerald GF, Stanton C. γ-Aminobutyric acid production by culturable bacteria from the human intestine [published correction appears in J Appl Microbiol. 2014;116(5):1384-6]. \u003cem\u003eJ Appl Microbiol\u003c/em\u003e. 2012;113(2):411\u0026ndash;417. doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1111/j.1365-2672.2012.05344.x\u003c/span\u003e\u003cspan address=\"10.1111/j.1365-2672.2012.05344.x\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eSolas M, Puerta E, Ramirez MJ. Treatment Options in Alzheimer\u0026acute;s Disease: The GABA Story. Curr Pharm Des. 2015;21(34):4960\u0026ndash;4971. doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.2174/1381612821666150914121149\u003c/span\u003e\u003cspan address=\"10.2174/1381612821666150914121149\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eQian XH, Xie RY, Liu XL, Chen SD, Tang HD. Mechanisms of Short-Chain Fatty Acids Derived from Gut Microbiota in Alzheimer's Disease. Aging Dis. 2022;13(4):1252\u0026ndash;1266. Published 2022 Jul 11. doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.14336/AD.2021.1215\u003c/span\u003e\u003cspan address=\"10.14336/AD.2021.1215\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eWenzel TJ, Gates EJ, Ranger AL, Klegeris A. Short-chain fatty acids (SCFAs) alone or in combination regulate select immune functions of microglia-like cells. Mol Cell Neurosci. 2020;105:103493. doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/j.mcn.2020.103493\u003c/span\u003e\u003cspan address=\"10.1016/j.mcn.2020.103493\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eChen Y, Xu J, Chen Y. Regulation of Neurotransmitters by the Gut Microbiota and Effects on Cognition in Neurological Disorders. \u003cem\u003eNutrients\u003c/em\u003e. 2021;13(6):2099. Published 2021 Jun 19. doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.3390/nu13062099\u003c/span\u003e\u003cspan address=\"10.3390/nu13062099\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eStrandwitz P, Kim KH, Terekhova D, et al. GABA-modulating bacteria of the human gut microbiota. Nat Microbiol. 2019;4(3):396\u0026ndash;403. doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1038/s41564-018-0307-3\u003c/span\u003e\u003cspan address=\"10.1038/s41564-018-0307-3\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eBlaak EE, Canfora EE, Theis S, et al. Short chain fatty acids in human gut and metabolic health. Benef Microbes. 2020;11(5):411\u0026ndash;455. doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.3920/BM2020.0057\u003c/span\u003e\u003cspan address=\"10.3920/BM2020.0057\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eZhou K. Strategies to promote abundance of Akkermansia muciniphila, an emerging probiotics in the gut, evidence from dietary intervention studies. J Funct Foods. 2017;33:194\u0026ndash;201. doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/j.jff.2017.03.045\u003c/span\u003e\u003cspan address=\"10.1016/j.jff.2017.03.045\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMacchione IG, Lopetuso LR, Ianiro G, et al. Akkermansia muciniphila: key player in metabolic and gastrointestinal disorders. Eur Rev Med Pharmacol Sci. 2019;23(18):8075\u0026ndash;8083. doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.26355/eurrev_201909_19024\u003c/span\u003e\u003cspan address=\"10.26355/eurrev_201909_19024\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eRodrigues VF, Elias-Oliveira J, Pereira \u0026Iacute;S, et al. Akkermansia muciniphila and Gut Immune System: A Good Friendship That Attenuates Inflammatory Bowel Disease, Obesity, and Diabetes. Front Immunol. 2022;13:934695. Published 2022 Jul 7. doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.3389/fimmu.2022.934695\u003c/span\u003e\u003cspan address=\"10.3389/fimmu.2022.934695\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eCani PD, Depommier C, Derrien M, Everard A, de Vos WM. Akkermansia muciniphila: paradigm for next-generation beneficial microorganisms [published correction appears in Nat Rev Gastroenterol Hepatol. 2022;:]. Nat Rev Gastroenterol Hepatol. 2022;19(10):625\u0026ndash;637. doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1038/s41575-022-00631-9\u003c/span\u003e\u003cspan address=\"10.1038/s41575-022-00631-9\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eRoopchand DE, Carmody RN, Kuhn P, et al. Dietary Polyphenols Promote Growth of the Gut Bacterium Akkermansia muciniphila and Attenuate High-Fat Diet-Induced Metabolic Syndrome. Diabetes. 2015;64(8):2847\u0026ndash;2858. doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.2337/db14-1916\u003c/span\u003e\u003cspan address=\"10.2337/db14-1916\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eAnh\u0026ecirc; FF, Roy D, Pilon G, et al. A polyphenol-rich cranberry extract protects from diet-induced obesity, insulin resistance and intestinal inflammation in association with increased Akkermansia spp. population in the gut microbiota of mice. Gut. 2015;64(6):872\u0026ndash;883. doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1136/gutjnl-2014-307142\u003c/span\u003e\u003cspan address=\"10.1136/gutjnl-2014-307142\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMezhibovsky E, Wu Y, Bawagan FG, Tveter KM, Szeto S, Roopchand D. Impact of grape polyphenols on Akkermansia muciniphila and the gut barrier. AIMS Microbiol. 2022;8(4):544\u0026ndash;565. Published 2022 Dec 22. doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.3934/microbiol.2022035\u003c/span\u003e\u003cspan address=\"10.3934/microbiol.2022035\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMcLeod A, Penalver Bernabe B, Xia Y, et al. Comparing the gut microbiome of obese, African American, older adults with and without mild cognitive impairment. PLoS One. 2023;18(2):e0280211. Published 2023 Feb 24. doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1371/journal.pone.0280211\u003c/span\u003e\u003cspan address=\"10.1371/journal.pone.0280211\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eAhl S, Guenther M, Zhao S, et al. Adiponectin Levels Differentiate Metabolically Healthy vs Unhealthy Among Obese and Nonobese White Individuals. J Clin Endocrinol Metab. Nov 2015;100(11):4172\u0026ndash;80. doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1210/jc.2015-2765\u003c/span\u003e\u003cspan address=\"10.1210/jc.2015-2765\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eChan WSA, Liew CF, Theng CTS, Oon HH. Serum Adiponectin Levels and Their Association With Cardiometabolic Risk Factors in Patients With Psoriasis. Cureus. May 15 2020;12(5):e8128. doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.7759/cureus.8128\u003c/span\u003e\u003cspan address=\"10.7759/cureus.8128\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\u003c/ol\u003e"}],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":true,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":false,"hideJournal":false,"highlight":"","institution":"","isAcceptedByJournal":true,"isAuthorSuppliedPdf":false,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":false,"isPdf":false,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"npj-science-of-food","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":false,"externalIdentity":"npjscifood","sideBox":"Learn more about [npj Science of Food](http://www.nature.com/npjscifood/)","snPcode":"41538","submissionUrl":"https://submission.springernature.com/new-submission/41538/3","title":"npj Science of Food","twitterHandle":"","acdcEnabled":true,"dfaEnabled":true,"editorialSystem":"stoa","reportingPortfolio":"NPJ","inReviewEnabled":true,"inReviewRevisionsEnabled":true},"keywords":"Black Raspberry, Helicobacter pylori, Obesity, Dementia","lastPublishedDoi":"10.21203/rs.3.rs-3899398/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-3899398/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"\u003cp\u003eAlzheimer's disease (AD) is the most common form of dementia. \u0026nbsp;\u003cem\u003eH. pylori\u003c/em\u003e infection and overweight\u003cem\u003e \u003c/em\u003ehave been implicated in AD via the gut-brain axis (GBA). This study aimed to determine supplementation of BRBs has a meaningful effect on the \u003cem\u003eH. pylori \u003c/em\u003einfection, overweight and AD development in a clinical trial setting. We conducted a randomized placebo-controlled clinical trial in patients with mild clinical dementia who also had \u003cem\u003eH. pylori \u003c/em\u003einfection and overweight. The study was carried out over 10 weeks, consisting of an 8-week intervention period (25g powder of black raspberries, BRBs, or placebo twice a day, morning and evening) and a 2-week follow-up. The primary outcomes were changes in Clinical Dementia Rating (CDR), Urea Breath Test (UBT), and Body Mass Index (BMI). Consumption of BRBs improved cognitive functions (p\u0026lt;0.00001), compared to the placebo group (p\u0026gt;0.05). Besides, BRB ingestion decreased \u003cem\u003eH. pylori\u003c/em\u003e infection and BMI (p\u0026lt;0.00001 and p\u0026lt;0.05 respectively) while placebo group stay statistically the same (p=0.98 and p=0.25 respectively). BRBs significantly decreased inflammatory markers, improved oxidative index, adiponectin (p\u0026lt;0.05) compared to placebo group, while adenosine monophosphate-activated protein kinase (AMPK) and leptin did not significantly change. BRBs modulated the abundance of several fecal probiotics, particularly, \u003cem\u003eAkkermansia muciniphila\u003c/em\u003e. Our results provided that BRBs suppressed \u003cem\u003eH. pylori \u003c/em\u003einfection and decreased BMI and rebalancing the gut microbiome, which could improve cognitive functions in AD patients. Longer and larger randomized clinical trials of BRB interventions targeting \u003cem\u003eH. pylori \u003c/em\u003einfection, overweight, or AD are warranted to confirm the results from this pilot trial.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eTrial Registration: \u003c/strong\u003eClinicalTrials.gov identifier: NCT05680532\u003c/p\u003e","manuscriptTitle":"Dietary Black Raspberry Supplementation as Natural Polyphenol Source Against Mild Dementia Patients with Overweight and Helicobacter pylori Infection","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2024-02-09 17:08:11","doi":"10.21203/rs.3.rs-3899398/v1","editorialEvents":[{"type":"communityComments","content":0},{"type":"decision","content":"revise","date":"2024-08-16T12:20:46+00:00","index":"","fulltext":""},{"type":"editorInvitedReview","content":"This content is not available.","date":"2024-08-13T13:25:13+00:00","index":2,"fulltext":"This content is not available."},{"type":"reviewerAgreed","content":"This content is not available.","date":"2024-08-13T04:35:53+00:00","index":2,"fulltext":"This content is not available."},{"type":"editorInvitedReview","content":"This content is not available.","date":"2024-05-01T00:47:48+00:00","index":1,"fulltext":"This content is not available."},{"type":"reviewerAgreed","content":"This content is not available.","date":"2024-04-17T06:14:12+00:00","index":1,"fulltext":"This content is not available."},{"type":"reviewersInvited","content":"","date":"2024-02-07T03:10:39+00:00","index":"","fulltext":""},{"type":"checksComplete","content":"","date":"2024-01-30T09:47:51+00:00","index":"","fulltext":""},{"type":"submitted","content":"npj Science of Food","date":"2024-01-26T08:07:26+00:00","index":"","fulltext":""},{"type":"editorAssigned","content":"","date":"2024-01-26T08:07:26+00:00","index":"","fulltext":""}],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"npj-science-of-food","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":false,"externalIdentity":"npjscifood","sideBox":"Learn more about [npj Science of Food](http://www.nature.com/npjscifood/)","snPcode":"41538","submissionUrl":"https://submission.springernature.com/new-submission/41538/3","title":"npj Science of Food","twitterHandle":"","acdcEnabled":true,"dfaEnabled":true,"editorialSystem":"stoa","reportingPortfolio":"NPJ","inReviewEnabled":true,"inReviewRevisionsEnabled":true}}],"origin":"","ownerIdentity":"ceeabc03-474b-445f-9e8e-064f29be342f","owner":[],"postedDate":"February 9th, 2024","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"published-in-journal","subjectAreas":[{"id":28618725,"name":"Health sciences/Health care"},{"id":28618726,"name":"Biological sciences/Biological techniques"}],"tags":[],"updatedAt":"2025-02-13T08:07:44+00:00","versionOfRecord":{"articleIdentity":"rs-3899398","link":"https://doi.org/10.1038/s41538-024-00356-w","journal":{"identity":"npj-science-of-food","isVorOnly":false,"title":"npj Science of Food"},"publishedOn":"2025-02-12 05:00:00","publishedOnDateReadable":"February 12th, 2025"},"versionCreatedAt":"2024-02-09 17:08:11","video":"","vorDoi":"10.1038/s41538-024-00356-w","vorDoiUrl":"https://doi.org/10.1038/s41538-024-00356-w","workflowStages":[]},"version":"v1","identity":"rs-3899398","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"redirect":"/article/rs-3899398","identity":"rs-3899398","version":["v1"]},"buildId":"qtupq5eGEP_6zYnWcrvyt","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}